

(12) PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. AU 199748131 B2
(10) Patent No. 732809

(54) Title
Compositions and methods for treating viral infections

(51)⁶ International Patent Classification(s)
C12Q 001/70 A61K 039/21
A23J 001/00 C07K 016/00

(21) Application No: 199748131 (22) Application Date: 1997 .10 .10

(87) WIPO No: W098/15658

(30) Priority Data

(31) Number (32) Date (33) Country
60/028194 1996 .10 .10 US

(43) Publication Date: 1998 .05 .05
(43) Publication Journal Date: 1998 .06 .25
(44) Accepted Journal Date: 2001 .05 .03

(71) Applicant(s)
Park Pacific Investments Pty Limited; Advance Group Investments Pty Limited; John Gerard Grounds; Advance Commercial Investments Pty Limited; Dean Charles Cornish; Daganur Biotechnology Pty Limited; Zacharia Investments Pty Limited; Ronald Edward Gristwood; ACN 083 017 127 Pty Limited; Bronam Investments Pty Limited; Neil Robert Cussen; Cravel Pty Limited; Gary Kenneth Urwin; Nabil Abdelmalek; Odette Abdelsayed; Wanis Wanis; Jeffrey Bryant; Victor Board and Geraldine Stuart; Talon Sydney Pty Limited; Arana Offset Pty Limited

(72) Inventor(s)
Frank B. Gelder

(74) Agent/Attorney
FREEHILLS CARTER SMITH BEADLE,MLC Centre,Martin Place,SYDNEY NSW 2000

(56) Related Art
J.VIROLOGY (1994), 68, PP 6006-6013
AIDS RESEARCH AND HUMAN RETROVIRUSES (1993), 9, 605-612

OPI DATE 05/05/98 APPLN. ID 48131/97
AOJP DATE 25/06/98 PCT NUMBER PCT/US97/18257



AU9748131

IN

(51) International Patent Classification ⁶ : C12Q 1/70, A61K 39/21, C07K 16/00, A23J 1/00		A1	(11) International Publication Number: WO 98/15658
			(43) International Publication Date: 16 April 1998 (16.04.98)
(21) International Application Number: PCT/US97/18257		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 10 October 1997 (10.10.97)		Published <i>With international search report.</i>	
(30) Priority Data: 60/028,194 10 October 1996 (10.10.96) US			
(71) Applicant: PROBE INTERNATIONAL [US/US]; Suite C-1, 220 Carroll Street, Shreveport, LA 71105 (US).			
(72) Inventor: GELDER, Frank, B.; 3024 Nottingham Drive, Shreveport, LA 71115 (US).			
(74) Agents: ERNST, Barbara, G. et al.; Rothwell, Figg, Ernst & Kurz, Suite 701 East, 555 13th Street N.W., Washington, DC 20004 (US).			
(54) Title: COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS			
(57) Abstract <p>Methods and compositions for treatment, diagnosis, and prevention of a virus comprise administering to a patient antibodies which react with regions of viral proteins and result in neutralization of infectivity and inactivation of functionally essential events in the life cycle of the virus. The antibodies recognize viral epitopes which fail to elicit an immune response in man when encountered through infection or naturally through the environment. In a preferred embodiment, the invention provides compositions and methods useful in the treatment and diagnosis of human immunodeficiency virus (HIV) infections.</p>			

COMPOSITIONS AND METHODS FOR
TREATING VIRAL INFECTIONS

Technical Field

5 The present invention relates generally to the treatment and prevention of viral infections. In particular, the invention provides compositions and methods for the production of antibodies and peptides useful in the treatment and diagnosis of human immunodeficiency virus (HIV) infections.

10 Background of the Invention

The diagnosis, treatment and prevention of viral infections is a primary focus of many medical researchers. Although compositions and methods of diagnosing, treating and vaccinating against a number of viral infections are known, there are still a number of viruses which are difficult to detect in man and for which no effective methods of treatment or vaccination against are known. Of these, one of the most significant, of course, is HIV.

20 The infectious agent responsible for acquired immunodeficiency syndrome (AIDS) and its prodromal phases, AIDS-related complex (ARC) and lymphadenopathy syndrome (LAS), is a lymphotropic retrovirus termed LAV, HTLV-III, ARV, and recently HIV as recommended by
25 the International Committee on Taxonomy of Viruses (Ref

299). Nomenclature herein employs these recommendations to designated viruses associated with AIDS and the strains thereof. Historic references to strains, which include LAV and ARV-2, are now named
5 HIV1 LAI and HIV1_{SF2}, respectively.

As the spread of HIV reaches pandemic proportions, the treatment of infected individuals and prevention of the transmission to uninfected individuals at risk of exposure is of paramount concern. A variety of
10 therapeutic strategies have targeted different stages in the life cycle of the virus and are outlined in Mitsuya and Broder, 1987, *Nature* 325:773. One approach involves the use of antibodies which bind to the virus and inhibit viral replication, either by interfering
15 with viral entry into host cells or by some other mechanism. Once the viral component(s) susceptible to antibody intervention are identified, it has been hoped that antibody reactivity sufficient to neutralize the infectivity of the virus could be generated and
20 administered to HIV-infected patients in the form of immune globulins or purified antibodies and that this passive immunization procedure would alter or reverse progression of HIV infection. In addition, it has been hoped that the vaccination of non-infected individuals
25 with selected epitopes modified to enhance MHC interactions would provide protection from subsequent infection following exposure to HIV.

The envelope glycoproteins of most retroviruses are thought to react with receptor molecules on the
30 surface of susceptible cells, thereby determining the virus' infectivity for certain hosts. Antibodies that bind to these envelope glycoproteins may block the interaction of the virus with the cell receptors, neutralizing the infectivity of the virus. See
35 generally, *The Molecular Biology of Tumor Viruses*, 534

(J. Tooze, ed., 1973); and *RNA Tumor Viruses*, 226, 236 (R. Weiss et al., eds., 1982); Gonzalez-Scarano et al., 1982, *Virology* 120:42 (La Crosse Virus); Matsuno and Inouye, 1983, *Infect. Immun.* 39:155 (Neonatal Calf
5 Diarrhea Virus); and Mathews et al., 1982, *J. Immunol.*, 129:2763 (Encephalomyelitis Virus). To date, therapeutic strategies directed at eliciting protective immune responses in man by vaccination with HIV
10 proteins/peptides have failed. In addition, neither high titer neutralizing antibodies recovered from HIV-infected patients nor monoclonal antibodies produced in mice have succeeded in altering the progression of HIV infection to AIDS and death. There is a need in the
15 art to identify alternate immunological targets on HIV which will elicit immune responses that will modify the course of HIV infection.

The general structure of HIV is that of a ribonucleo-protein core surrounded by a lipid-containing envelope which the virus acquires during the
20 course of budding from the membrane of the infected host cell. Embedded within the envelope and projecting outward are the viral encoded glycoproteins. The envelope glycoproteins of HIV are initially synthesized in the infected cell as a precursor molecule of
25 150,000-160,000 Daltons (gp 160), which is then processed in the cell into an N-terminal fragment of 110,000-120,000 Daltons (gp 120) to generate the external glycoprotein, and a C-terminal fragment of 41,000-46,000 Daltons (gp 41), which is the
30 transmembrane envelope glycoprotein.

For the reasons discussed above, the gp 120 glycoprotein of HIV has been the object of much investigation as a potential target for interrupting the virus' life cycle. Sera from HIV-infected
35 individuals have been shown to neutralize HIV in vitro,

and antibodies that bind to purified gp 120 are present in these sera, (Robert-Guroff et al., 1985, *Nature* 316:72; Weiss et al., 1985, *Nature* 316:69; and Mathews et al., 1986, *Proc. Natl. Acad. Sci. U.S.A.*, 83:9709).

- 5 Purified and recombinant gp 120 stimulated the production of neutralizing serum antibodies when used to immunize animals (Robey et al., 1986, *Proc. Natl. Acad. Sci. U.S.A.*, 83:7023; Lasky et al., 1986, *Science*, 233:209) and a human (Zagury et al., 1986, *Nature* 326:249). Binding of the gp 120 molecule to the CD4 receptor also has been shown and monoclonal antibodies which recognize certain epitopes of the CD4 receptor have been shown to block HIV binding, syncytia formation, and infectivity. McDougal et al., (1986, *Science* 231:382) and Putney et al. (1986, *Science* 234:1392) elicited neutralizing serum antibodies in animals after immunizing with a recombinant fusion protein containing the carboxyl-terminal half of the gp 120 molecule and further demonstrated that glycosylation of the envelope protein is unnecessary for a neutralizing antibody response.

- Shortly after HIV infection the immune system of man responds to the virus with both antibody production and cell mediated immune responses. A review of the immune responses to retroviruses has been published (Norley, S., and Kurth R., 1994: *The Retroviridae*, Vol E, J.A. Levy, ed., pp. 363-464, Plenum Press). Human antibodies specific for a number of HIV proteins including gp 160, gp 120, p66, p55, gp 41, p32, p24, and p17 have been reported (Carlson, 1988, *J.Am. Med. Assoc.* 206:674). The initial antibody response in man to HIV is directed to p17 and p24, followed by gp 120/160, then by gp 41, p66/55 and finally p32 (Lange 35 et al 1986, *Br. Med. J.* 292:228). As HIV infection progresses into AIDS antibody levels

to p17 and p24 markedly fall to undetectable limits and are replaced by p17 and p24 antigenemia. Antibody titers to p32 and p55 also decline but to a lesser degree (McDougal et al 1987 J. Clin. Invest. 80:316).

5 However, substantial amounts of antibodies to gp 160/120 persist throughout the entire course of HIV infection. During the early phases of HIV infection an elevation in total immunoglobulins is observed and this increased quantity of antibody is specific for HIV and

10 predominantly directed to gp 120, (Amadori et al., 1988 Clin. Immunol. Immunopathol. 46:342; Amadori et al, 1989, J. Immunol 143:2146). Possible mechanisms for this HIV specific hyper gamma globulinemia have been reviewed by Barker E. et al 1995: The Retroviridae Vol

15 4, J.A. Levy, ed. pp 1-96 Plenum Press. Functional properties and epitopes targeted by these antibodies produced during HIV infection have been described and include epitopes which are susceptible to antibody mediated neutralization. These primary target epitopes

20 are primarily located on the envelope protein gp160 (gp120/gp41) and the gag protein p17; for review see Levy, 1994 Am.Soc. Micro; Nixon et al, 1992 Immunol 76:515. Neutralizing antibodies to HIV envelope protein have been identified and bind to conserved and

25 divergent domains on gp 120. These include regions localized to the CD4 binding regions (Linsley et al 1988 and Thali et al, 1992); the second and third variable loop domains (Fung et al, 1992 and Haigwood et al 1990); and carbohydrate moieties (Benjouad et al,

30 1992 and Feizi and Larkin, 1990). Other neutralization sites have been identified on the external portion of gp 41 and a binding site on p17 (Changh et al, 1986). Early studies suggested that the presence of neutralizing antibodies lead to a more favorable

35 clinical outcome, (Robert-Guroff et al, 1985).

However, these studies employed selected sera with high neutralizing capacity against laboratory strains of HIV and not against autologous HIV isolates (Homsy et al, 1990; Tremblay and Wainberg, 1990). Subsequent
5 investigation demonstrated that autologous antibody had little or no neutralizing activity against autologous HIV isolates (Homsy et al, 1990). The lack of susceptibility to antibody mediated neutralization in the presence of a neutralizing antibody is thought to
10 result from the development of escape mutants that appear after seroconversion (Arendrup et al, 1992) and throughout the infection as new antibody specificities are produced. The clinical relevance of neutralizing antibodies produced as a consequence of HIV infection
15 is unclear. However, it is clear that in spite of a vigorous immune response to HIV in individuals infected with HIV, progress to AIDS and, ultimately, death as a consequence of immune dysfunction predominates. Accordingly, new methods of treatment are sought.

20 Objects of the Invention

It is an object of this invention to identify neutralizing regions of viral proteins which fail to elicit immune responses in man but do elicit immune responses in non-human mammals and to produce
25 antibodies reactive with these regions. It is a further object of this invention to use these identified neutralizing regions of proteins and the antibodies reactive with them in the diagnosis, treatment and prevention of disease caused by the
30 virus. Further objects of this invention will be apparent from the description of the invention detailed below.

Summary of the Invention

In accordance with the present invention there are provided methods and compositions for the treatment, diagnosis and prevention of viral infection by the use of antibodies which react with regions of viral proteins to neutralize and inactivate functionally essential events in the life cycle of the virus. The antibodies recognize viral epitopes which fail to elicit an immune response in humans when encountered through infection or through environmental exposure but do elicit an immune response in non-human mammals.

Selected epitopes that react with nonhuman anti-viral antibodies but not with human anti-viral antibodies are identified. These epitopes escape surveillance by the human immune system through molecular mimicry to human proteins and in some instances are composed of amino acids susceptible to enzymatic cleavage in antigen processing cells. Desired epitopes are enzymatically cleaved by human enzymes and therefore are not processed for immune presentation.

Peptides representing these epitopes can be synthesized, optionally modified, and conjugated to a macrocarrier adjuvant to elicit antibody responses in non-humans. The preferred adjuvant is a microparticle comprising multiple repeats of muramyl dipeptide extracted from *Propionibacterium acini*.

Antibodies and peptides of this invention can be used in immunoassay configurations to identify species specific epitopes and to quantitate viral antigens in human tissues and fluids. In a preferred embodiment, the invention provides antibody and peptide compositions and methods useful in the treatment and diagnosis of individuals infected with the virus.

In a preferred embodiment, the virus of interest is HIV.

Detailed Description of the Invention

5 The present invention provides novel compositions and methods for diagnosing and neutralizing viral infections. The invention will be described in detail with a focus on a preferred embodiment, in which the virus of interest is HIV. It is to be understood, however, that the principles of the invention can be
10 used to identify neutralizing regions of proteins of other viruses and to produce antibodies reactive with those proteins that can be used to diagnose, treat and prevent infections caused by these other viruses as well.

15 Focusing now on HIV, this invention provides novel compositions and methods for neutralizing HIV infection and preventing or substantially inhibiting HIV infectivity, cell to cell transmission, and virus production in the infected host. More specifically,
20 HIV protein sequences containing epitopes which fail to elicit an immune response in man when encountered through infection or naturally through the environment are utilized as described in detail below to produce antibodies in non-human mammals which can be
25 administered to neutralize HIV infectivity, facilitate killing of infected CD4 lymphocytes, and inactivate essential steps in the life cycle of HIV. The term "neutralizing region" indicates those portions of HIV, particularly HIV proteins, containing amino acid
30 segments defining one or more epitopes reactive with antibodies which, either individually or in combination with other antibodies of the present invention, are capable of neutralizing HIV infections. Suitable

assays for evaluating neutralization are well known and can include assays which measure reduction of HIV infections in T-cell lines, reduction of plaque forming units of VSV (HIV) pseudo types bearing the envelope glycoproteins of HIV, syncytial inhibition tests, and virion-receptor binding tests. The term "inactivating region" indicates those segments of HIV proteins which contain one or more epitopes which when reacted with antibodies of this invention, either individually or in combination, inactivate functionally important events in the life cycle of HIV. Suitable assays to evaluate antibody-mediated destruction of HIV infected lymphocytes are well known and can include antibody dependent cell mediated cytotoxicity, complement mediated lysis, and natural killer (NK) assays. Suitable assays for measuring antibody-mediated inactivation of essential steps of the life cycle of HIV include assays which determine inactivation of reverse transcriptase, or measure polymerase and protease activity, or which evaluate antibody-mediated complement dependent changes in nuclear capsid permeability exposing viral RNA to ribonuclease degradation. As desired, the neutralizing activity can be compared to antibody reactivity in immunochemical assays, such as immunofluorescence, immunoblot, enzyme linked immunoassay, and radioimmunoassay.

The present invention is based on the discovery that epitopes which are functionally important in the life cycle of HIV, but not immunogenic in man, can be identified and characterized employing antibodies produced in selected mammalian species other than man. In addition, it has been discovered that the immunological non-responsiveness in man to these regions is a function of molecular mimicry and lack of

MHC associated events, including antigen presentation through required MHC HLA class 1 and HLA class 2 associated events. With molecular mimicry the epitope is seen as self and is not responded to under normal circumstances. With lack of MHC associated events in antigen presentation several steps are involved and failure of any one step can result in the absence of an immunological response to the antigen.

Peptide regions containing multiple overlapping epitopes and antibodies to these epitopes have been produced and are shown to neutralize and inactivate essential steps in the life cycle of HIV *in vitro*. In addition, HIV-infected patients with AIDS have been treated with antibodies to these peptide regions, resulting in rapid reduction in blood born infectivity measured by total culturable infectious dose (TCID). Treatment of chronic AIDS patients with these antibodies has resulted in marked clinical improvement, including weight gain, resolution of opportunistic infections, decreased incidence and severity of infections and doctor visits and resolution of HIV-associated neuropathy. The patients further have shown immunological recovery, as defined by a reduction of HIV-RNA, increased CD4 number, increased CD8 number and restoration of the cytokine system associated with improved CD4 and CD8 numbers and function.

Identification of Epitopes and Production of Antibodies

The majority of immune reactions target immunodominant epitopes. HIV epitopes are most frequently identified and mapped by various immunological methods which employ antisera to HIV, cytotoxic T lymphocyte reactivity to HIV epitope targets and helper lymphocyte antigen presentation of

HIV epitopes. Synthetic peptides of known sequence which mimic HIV sequence can be employed competitively or noncompetitively using well known assays to confirm these observations. It is to be understood that stimulation of the immune system can lead either to enhancement or suppression of the immune response. Factors which govern this include:

- 10 A. The sub population of lymphocytes stimulated by the immunogen (Suppressor versus Helper).
- B. The micro-environment, including cell population residing therein, which contact the immunogen first.
- 15 C. The type of cytokines present in the micro-environment at the time of effector cell contact with the immunogen.
- 20 D. The type of cytokines elicited following effector cell contact with the immunogen.
- E. Structural and biochemical composition of the immunogen.
- 25 F. The amino acid sequence of the immunogen and its susceptibility to protease degradation by proteases in the micro environment.

From preliminary experiments, the following properties were determined to be fundamentally important in determining the potential value of certain proteins and peptides for use in the production of antibodies which are intended for passive immunotherapy application in the treatment or palliation of disease processes in man and, in particular, infection with HIV at all stages including AIDS:

- 35 A. The immunogen must lack epitope determinants that are expressed on human

cells and tissues when employed to produce antibody for use in passive immunotherapy with the following exceptions:

- 5 1. Antigen distribution is restricted to sequestered and/or unavailable locations to the antibody.
- 10 2. The antigen is expressed during developmental phases which permit the use of antibody at specific times during the developmental cycle, when antigen is not available.
- 15 3. Epitope location within the host is not adjacent to a vital structure.
- 20 4. Antigen distribution on host cell is at a density lower than required to produce injury but favorable on the desired target resulting in selective targeting.
- 25 5. The target to normal ratio must be sufficiently different and favor antibody delivery to the desired target.
- 30 B. The number of peptide repeats delivered to an antigen-presenting cell directly influences the magnitude of the immunological response.
- C. The epitope must not be present in body fluids at concentrations which would neutralize antibody and prevent targeting.

To date vaccine development has focused on
35 designing better technology to amplify responses to targets to which the immune system of man responds, and passive immunotherapy has resulted in inconclusive results. Disclosed herein are alternate targets on HIV which do not elicit immune events in man as well as a
40 new configuration to deliver antigen which results in immune reactions to HIV not previously attainable. The

methods disclosed herein focus on the treatment of HIV and AIDS, but it is to be understood that the formulations of this invention have broad application. The antibody response in goats demonstrates utility of invention by way of antibody production to key targets on HIV, and by way of treatment which results in clinical improvement of AIDS. This technology has broad application in vaccine development.

Successful immune induction to antigen challenge requires the presentation of multiple epitope repeats by an antigen-presenting cell (APC) through MHC events. Epitopes which are most immunogenic are in an amphipathic configuration with a hydrophobic amino acid on one terminus, a hydrophilic amino acid on the other terminus, contain amino acids consistent with the formation of amphipathic helices; i.e., they lack helix breaking amino acids, such as proline, and lack carbohydrate. Sequences which lack amino acids that are susceptible to protease degradation by proteases in the micro-environment are especially desired.

To identify immunological targets on HIV with functional importance, immunogenic regions on HIV-related proteins in animal species other than man were determined. Goats were immunized with purified HIV lysate with and without carbohydrate groups removed. Removing carbohydrate residues from HIV proteins has little effect on the immunological response to the proteins yet can expose hidden epitopes. HIV lysates obtained commercially were further purified to remove proteins of tissue culture origins including human HLA class 1 antigens, HLA class 2 antigens, and beta-2-microglobulin. Following immunization, antisera from the goats were tested employing competitive immunoassay methodology to identify HIV peptides not recognized by antibodies pooled from HIV-infected patients. Pools of

human HIV antisera were prepared from selected patient sera with high neutralizing and Western Blot activity and employed as competitive antibodies using standard competitive immunoassay methods. A broad spectrum of goat antibodies were identified which reacted with HIV determinants immunologically distinct from those recognized by the human anti-HIV antisera pools.

Those skilled in the art recognize that other animal species could be used to produce antibodies to these epitopes and that such antibodies could function in ADCC and complement mediated reactions. Other suitable animal species for the production of antibodies include, but are not limited to, sheep, rabbits, horses, cows and mice.

The epitope reactivity of the anti-HIV antibodies was characterized using twelve-mer peptides spanning the linear amino acid sequences of HIV_{1SF2}. Peptides of this size react well with antibodies, can be synthesized easily and can be prepared in highly purified form. Peptides were synthesized by and purchased from Purification Systems, Inc. The synthetic peptides were combined with peroxidase labeled goat anti-HIV antibodies and combined with each of two sets of microtiter wells coated with HIV. One set was blocked with human IgG anti-HIV; the other set was not. The percent of peptide inhibition of goat anti-HIV binding to HIV protein sites blocked with human anti-HIV was determined.

When inhibition of binding was observed with a specific synthetic peptide, additional peptides were synthesized with amino acid sequences overlapping that of the original inhibiting peptide to further define the epitope sequences.

The location of the epitopes on the HIV proteins recognized by goat anti-HIV IgG but not human anti-HIV

IgG were further evaluated and confirmed using HIV peptide-HRP conjugates as the identification markers. In this assay, HIV proteins were absorbed to supports such as microtiter plate wells or precision polystyrene beads. Twelve-mer peptides spanning the linear amino acid sequence of HIV_{1SF2} were covalently attached to horseradish peroxidase. Human and goat anti-HIV reactivity were measured independently with anti-HIV reactivity from human and goat bridging the native epitopes adsorbed to the support and to the peptide epitope covalently attached to peroxidase. With this procedure, detailed in Example 8, only exact epitopes contained within the synthetic peptide were recognized.

Once peptides having significant mimicry with human proteins have been identified, those sequences which have functional importance in the life cycle of HIV are determined. This is done, as described below and illustrated in Example 8, by generating antibodies to candidate peptides and then testing those antibodies for their effects on HIV infectivity and viral neutralization.

As noted above, a number of specific epitope regions have been identified and nine are described in detail below with reference to the HIV_{1SF2} sequence unless otherwise indicated. Amino acid residue designations set forth below and throughout this application for HIV_{1SF2} are from the Los Alamos Data Bank (AIDS Virus Sequence Data Base, Los Alamos National Laboratories, Theoretical Division, Los Alamos, N.M. 87545). Amino acid residue designations set forth below and throughout this application for HIV2NZ are from the Ex Pasy World Wide Web Molecular Biology Server of the Geneva University Hospital and the University of Geneva, and the BioAccelerator available through Compugen Ltd. at the Weizman

Institute, Israel, and Akira Ohyama, BioScience Systems Department, Mitsuey Knowledge Industry Co., Ltd., Tokyo, Japan. Those skilled in the art will appreciate that additional analogous regions ("homologs") from
5 other HIV isolates can be identified based upon their location within related proteins from various isolates. In practice, such homologs can be identified by reference to HIV1_{SF2} sequence data as follows:

(a) the amino acid sequences of HIV isolates and
10 HIV1_{SF2} can be aligned to obtain maximum homology between the two sequences, generally at least about 75% identify between the sequences;

(b) once an amino acid sequence is aligned to the corresponding location within HIV1_{SF2} proteins will
15 demonstrate immunological mimicry, similarity, or identity with HIV1_{SF2} as defined by retention of antibody reactivity to the mimicked or homologous sequence. Peptides from other HIV isolates and their amino acid sequences so identified typically will
20 immunologically mimic corresponding regions on HIV1_{SF2}.

This method of identifying key epitopes can be applied to HIV strains that are yet to be discovered. For example, as new strains of HIV are identified, their envelope and core amino acid sequences can be
25 aligned with that of HIV1_{SF2} to obtain maximum sequence homology with that strain. The methods by which the sequences are aligned are known to those skilled in the art. In aligning the sequences it is desired to maintain as much homology between cysteine residues as
30 possible. The amino acid sequence(s) of the new HIV strain or species which corresponds to the location of the peptides specifically disclosed herein can be synthesized and used in accordance with the invention.

It is not necessary to the present invention that
35 the epitopes contained within such sequences be cross-

reactive with antibodies to all strains or species of HIV. Peptides encompassing immunological epitopes which distinguish one species or serogroup over another will find utility in identifying particular species or serogroups and may assist in identifying individuals infected with one or more species or serogroups of HIV. They also can be useful in combination with other peptides, from either a homologous region or another neutralizing region, in therapeutic regimens.

The amino acid sequences of this invention typically comprise from about 5 to about 50 amino acids and comprise an epitope region or multiple epitope regions located on HIV proteins that fail to elicit a protective immune response in man when encountered through infection or environmental contact but do elicit a response in a non-human mammal. Preferably, the sequences comprise between about 5 and 35 amino acids. Synthetic peptides or treated lysates of natural HIV proteins containing the desired amino acid sequences are used to immunize animals which respond immunologically to them and produce antibodies which have therapeutic value in treating HIV infections.

The amino acid sequences or peptides of interest fail to elicit an immune response in man through mimicry of epitopes on human and other proteins. Of particular interest are peptide epitopes shared between HIV proteins and human alpha fetoprotein, aspartyl protease, deoxyuridine 5'-triphosphate nucleotidohydrolase, eosinophil cationic protein, eosinophil-derived neurotoxin and ribonuclease 4 precursor and peptide epitope regions mimicked by neurotoxins from Bungaris Naja, Dendoaspis, Psudechis, or Androctonus Centruroides.

In the discussion which follows, reference is made to a number of human proteins and neurotoxins using

standard identifying abbreviations for the proteins.
Set forth below is a table which sets forth these
abbreviations and the full names of the proteins to
which they correspond:

Human Proteins With Sequence Similarity to HIV Proteins

	Swiss Prot ID XXXX-Human	Protein
	ACE	angiotensin-converting enzyme precursor
5	ACHE	acetyl choline receptor protein
	3BH1	3-beta hydroxy-5-ene steroid dehydrogenase type I
	3BH2	3-beta hydroxy-5-ene steroid dehydrogenase type II
	41BL	4-1BB ligand
	BLSA	beta-lymphocyte antigen precursor
10	CATD	cathepsin D precursor
	CD69	early activation antigen CD69
	CD81	CD81 antigen
	CO02	tumor-associated antigen CO-029
	CP11	cytochrome P450 1A1
15	CYRP	cytokine receptor common beta-chain precursor
	CYPC	peptidyl-prolyl cis-trans isomerase C
	DIAC	di-N-acetylchitobiase precursor
	DUT	deoxyuridine 5'-triphosphate nucleotidohydrolase
	ECP	eosinophil cationic protein precursor
20	EV2B	ectotropic viral integration site 2B protein
	FETA	alpha fetoprotein
	FOL1	folate receptor alpha precursor
	GSHR	glutathione reductase
	IL9	interleukin 9 precursor
25	IN19	interferon-inducible protein 9-27
	INIU	interferon-inducible protein I-8U
	INR2	interferon alpha/beta receptor beta-chain precursor
	KLTK	leukocyte tyrosine kinase receptor precursor
	KPCL	eta type protein kinase C
30	LBP	lipopolysaccharide binding protein precursor
	LCAT	lecithin-cholesterol acyltransferase
	LECH	asialoglycoprotein receptor 1

	LFA3	lymphocyte function-associated antigen-3 precursor
	LMA1	laminin alpha-1 chain precursor
	LONN	mitochondrial LON protease homolog precursor
	LONM	mitochondrial LON protease homolog precursor
5	LYOX	protein-lysine 6-oxidase precursor
	MAG1	melanoma associated antigen 1
	MAG2	melanoma associated antigen 2
	MAG3	melanoma associated antigen 3
	MC5R	melanocortin-5 receptor
10	MYSE	embryonic myosin heavy chain
	NOL1	proliferating-cell nucleolar antigen P120
	NRM1	natural resistance-associated macrophage protein 1
	NT3	neurotrophin-3 precursor
	NTCR	sodium and chloride-dependent creatin transporter 1
15	NXS1-NAJAT	cobrotoxin
	PA2M	membrane associated phospholipase A2 precursor
	PIP5	phospholipase C-gamma-2
	PGDS	alpha-platelet derived growth factor precursor
	PLK	proteoglycan link protein precursor
20	POL1	retrovirus-related pol polyprotein
	PSS1	phosphatidylserine synthase I
	RENI	renin precursor
	RNKD	nonsecretory ribonuclease precursor
	S5A2	3-oxo-5-alpha-steroid-4-dehydrogenase 2
25	SDC1	syndecan-1 precursor
	SDC4	syndecan-4 precursor
	SEMI1	semenogelin 1 protein precursor
	SON	SON protein
	SPCB	erythrocyte spectrin beta-chain
30	SRE1	sterol regulatory element binding protein 1
	SYV	valyl-tRNA synthetase
	TCO2	transcobalamin II precursor
	TGL3	protein-glutamine glutamyltransferase E3 precursor

TFPI	tissue factor pathway inhibitor precursor
TRFL	lactotransferrin precursor
TYK2	non-receptor tyrosine-protein kinase
VPRT	retrovirus related protease
WNT2	WNT-2 protein precursor
ZN45	zinc finger protein 45

The amino acid sequences of nine of the highly conserved epitope regions discussed above are provided below. Three of these regions are on the envelope glycoproteins gp120 (two targets) and gp41 (one target), one is on the reverse transcriptase heterodimer p66/55, and one is on protease p10. Additional targets are on the Gag precursor (p55/Gag) with sites on p17 (two targets), p24 and p7.

One epitope region on HIV1_{SF2} gp120 extends from amino acid residue 4 through 27 and a second extends from amino acid residue 54 through 76 of HIV1. Antibodies to epitope regions located on gp120 function synergistically to effect the release of gp120 from gp41. The release of gp120 from gp41 is antibody dose dependent and can be demonstrated by neutralization assays, such as TCID, which measure HIV infectivity.

An epitope region of a neutralizing or inactivating region of gp120 of HIV2_{NZ} also has been determined. The sequence of HIV2_{NZ} envelope glycoprotein gp120 has been mapped, and from about amino acid residue 7 through 43 is a region mimicking a sequence of HIV1_{SF2} gp120 and certain human proteins. Antibody targeting the region results in dissociation of HIV2 gp120 from gp41, which correlates with a reduction in infectivity.

A third HIV envelope glycoprotein target for HIV1_{SF2} was located at amino acid residues 502-541 of gp41 transmembrane glycoprotein. Antibody targeting of

this region in the presence of complement results in an antibody dependent complement mediated lysis of the HIV envelope glycoprotein and marked reduction in HIV infectivity.

5 In addition to the envelope glycoprotein epitope regions, another HIV1 epitope region of interest includes amino acid residues 254 through 295 of the reverse transcriptase heterodimer p66/55. Antibody targeting of this region results in an antibody dose
10 dependent reduction in reverse transcriptase activity. Also of interest is the epitope region encompassing amino acid residues 69-94 of protease p10. Antibody targeting of this region results in an antibody dose dependent reduction in protease activity.

15 The targets on reverse transcriptase and protease are in conserved regions adjacent to the enzyme active site, which is well-known for its mutation and subsequent resistance to competitive inhibitors. The antibody-mediated inactivation results from a steric or
20 conformational change in the enzyme with secondary loss of activity. This method of inactivation functions independently and is not influenced by mutation in the enzyme active site and is irreversible.

 Also of interest are three epitope regions within
25 the Gag gene. Specifically, amino acid residues 166 through 181 of Gag gene protein p24, one target at amino acid residues 2 through 23 and a second target at amino acid residues 89 through 122 of Gag gene protein p17 and amino acid residues 390 through 410 and 438
30 through 443 of Gag gene protein p7 are useful in this invention. Antibodies targeting these regions result in disruption of the nuclear capsid following lysis of the HIV envelope by the antibodies described above. This targeting culminates with exposure of HIV RNA to
35 plasma RNase degradation. Additionally, the targets on

p17 is exposed on the surface of infected lymphocytes following budding. This provides an additional target for ADCC lysis of infected lymphocytes.

One of the specific peptides set forth above,
5 comprising at least one epitope not recognized by
antibodies from HIV-infected patients but recognized by
goat anti-HIV antibodies, is the peptide comprising
amino acid residues 4 through 27 of HIV1_{SF2} envelope
gp120 protein and linear epitope-containing
10 subsequences thereof, which has the following sequence:

K G T R R N Y Q H L W R W G T L L L G M L M I C

This peptide mimics human proteins FOL1, NTCR, PIP5,
PSS1, KLTK, MC5R, ECP, INIU, INI9, VPRT, CD69, MYSE,
RNKD, ACHE, TCO2, LCAT, MAG1, MAG2, MAG3 and LYOX.

15 A second epitope region from the HIV1_{SF2} gp120
envelope glycoprotein extends from amino acid residue
54 through 76, which has the sequence:

A S D A R A Y D T E V H N V W A T H A C V P T

This peptide mimics proteins CYRB and SYV.

20 A third epitope region of interest in the envelope
of HIV1_{SF2} extends from amino acid residue numbers 502
through 541 of glycoprotein gp41. This peptide has the
following amino acid sequence:

HIV1_Env502

25 R V V Q R E K R A V G I V G A M
F L G F L G A A G S T M G A V S
L T L T V Q A R 502-541

This peptide mimics human proteins CYPC, TYK2, ACHE,
NTCF, NTCR, CD81, 41BL, NIDO, GSHR, COO2 and TCO2.

In another specific embodiment, an epitope region of interest is that of amino acid residues 2 through 23 of the HIV_{1SF2} Gag protein p17. This peptide has the sequence:

5 G A R A S V L S G G E L D R W E K I R L R P

This peptide mimics human proteins TFPI, PA2M, BLSA, ECP, and FETA and certain neurotoxins, such as NXS1 and NAJAT. The peptide has a hydrophobic sequence which binds to and targets host cell membrane and function
10 mimics cellular translation protein Src.

A second target on HIV_{1SF8} p17 extends from amino acid residue 89 through 122. This peptide has the sequence:

L Y C V H Q R I D V K D T K E A L E K I E E E Q N K S K.

15 This peptide mimics FETA and TRIC.

Another peptide of interest is that of amino acid residues 166 through 181 of the Gag gene protein p24 and epitope containing subsequences therein. This peptide has the sequence:

20 P E V I P M F S A L S E G A T P

This peptide mimics human proteins FETA and TRFL.

A third Gag gene protein epitope region of interest is the peptide having amino acid residues 390 through 410 and 438-443 of Gag gene protein p7 and
25 epitope containing subsequences thereof. This peptide has the sequence:

K T V K C F N C G K E G H I A K N C R A P + K I W S S Q

This peptide mimics human FETA and RNA binding proteins. This peptide contains a zinc binding domain
30 which interacts with, and binds to, viral RNA. Antibodies to this region enhance the removal of premature HIV devoid of envelope following the lysis of infected CD4+ lymphocytes.

Also of interest as an epitope region is the
35 peptide of amino acid residues 69 through 94 of the

protease p10 and epitope-containing subsequences thereof. This peptide has the sequence:

R I G G Q L K E A L L D T G A D D T V L E E M N L P

This peptide sequence mimics human proteins REN1, BLSA, VPRT and CATD. Antibodies to this sequence inhibit the protease activity of HIV.

A further specific sequence useful in this invention is a sequence encompassing amino acid residues 254 through 295 of HIV1 reverse transcriptase heterodimer p66/55. This peptide has the sequence:

G L K K K K S V T V L D V G D A Y F S V P L D K D
F R K Y T A F T I P S I N N E T P

This peptide sequence mimics human proteins POL1 and ECP.

As noted above, other strains of HIV also can be used to obtain peptides and antibodies in accordance with the present invention. Useful peptides from other strains can be determined by comparing and aligning the sequence of another strain to the sequence of HIV1_{SF2} or HIV2_{NZ} and finding that part of the sequence homologous to the epitopes of interest identified for HIV1_{SF2} or HIV2_{NZ}.

A sequence of interest in HIV2_{NZ} identified by the method of this invention is in the env gp120 open reading frame and extends from amino acid residue numbers 7 through 43. This peptide has the following sequence:

Q L L I A I V L A S A Y L I H C K Q F
V T V F Y G I P A W R N A S I P L F

This peptide mimics human proteins IL9, SRE1, NRM1, LBP, NOL1, S5A2, LMA1, LECH, LFA3, KPLC, FETA, 3BH2, 3BH1, INR2 and EV2B.

For example, once the desired amino acid sequences have been identified, antibodies which recognize these sequences are obtained. Such antibodies can be obtained using proteins containing the peptides
5 isolated from HIV lysates, synthetic peptides, bacterial fusion proteins and proteins/peptides from phylogenetically unrelated sources which contain the desired epitopes.

If viral lysates are to be used, a protein lysate
10 of a single HIV strain can be used, or a mixture of lysates of two or more different strains can be used. If a mixture of lysates is used, the mixture can comprise lysates of different HIV1 strains or a combination of at least one HIV1 strain and at least
15 one HIV2 strain. A preferred mixture is a combination of lysates from HIV1_{BAL}, HIV1_{MN} and HIV2_{NZ}.

Viral lysates initially are treated to remove lipids and other impurities from the HIV proteins. The HIV protein mixture then is treated to remove
20 contaminants of cell culture origin, including human leukocyte antigen (HLA), class I and class II antigens. Methods for removing these antigens are known in the art and include employing monoclonal anti-HLA class I and anti-HLA class II antibodies and immunoaffinity
25 procedures; one method is set forth in detail in Example 3 below.

In addition, it has been found that carbohydrates of the HIV proteins must be removed; phylogenically preserved carbohydrates determinants otherwise would
30 stimulate immune responses when the HIV proteins are administered to an animal, resulting in the production of antibodies which would be cytotoxic against human tissues. The proteins are treated with enzymes known to those skilled in the art to remove carbohydrates,

including PGNase, neurominidase and glycosidase. One such method is described in detail in Example 3.

The mixture of treated HIV proteins then can be used to immunize an animal to produce antibodies to the peptides of interest. Desirably, the mixture contains approximately equal amounts of the proteins comprising the peptides or epitope regions of interest. That is, desirably they are provided in proportions of approximately 1:1 and the difference in molar ratios between any two peptides is no greater than about 10:1, preferably 3:1.

Alternatively, synthetic peptides can be used as the immunogen. If synthetic peptides are used the amino acid sequence of any desired peptide can be modified by, for example, using a substituted or truncated form of the amino acid sequence.

Amino acid substitutions can be made to avoid predicted enzymatic cleavage that can occur during antigen processing at a particular amino acid moiety, to force amphipathic conformation to meet required MHC-associated antigen presentation and to provide sufficient length for HLA presentation should cleavage occur at or near the epitope boundary. Truncated sequences are selected such that the peptide will retain conformity to epitope length requirements as predicted by MHC class 1 and class 2 antigen presentation motifs. More extensive guidelines on desirable amino acid substitutions are given below as part of the section on synthetic peptides. In addition to substituted and truncated sequences, extended sequences can be prepared in which additional amino acids are added at either end of a selected epitope region for the purpose of facilitating attachment to solid phase supports and macromolecular carriers.

As an example, useful truncated sequences of the peptide extending from amino acid residue 502 through 541 of HIV1_{SF2} gp41 discussed above include a peptide with the sequence of amino acid residues 512-531:

5 G I V G A M F L G F L
 G A A G S T M G A

and also a sequence extending from amino acid residue 518 through amino acid residue 527:

F L G F L G A A G S

- 10 Another particularly useful truncated peptide is a truncated sequence of the peptide extending from amino acid 7 through 43 of gp120 of HIV2_{NZ}, has the following sequence

L L I A I V L A S A Y L I H C K Q

- 15 The peptide can be prepared in a wide variety of ways. The peptide, because of its relatively small size, can be synthesized in solution or on a solid support in accordance with conventional techniques. Various automatic synthesizers are commercially
20 available today and can be used in accordance with known protocols. See, for example, Stewart and Young, *Solid Phase Peptide Synthesis*, 2nd ed., Pierce Chemical Co., 1984; and Tam et al., *J. Am Chem. Soc.* (1983) 105:6442.

- 25 Alternatively, hybrid DNA technology can be employed where a synthetic gene is prepared by employing single strands which code for the polypeptide or substantially complementary strands thereof, where the single strands overlap and can be brought together
30 in an annealing medium so as to hybridize. The hybridized strands then can be ligated to form the complete gene, and, by choice of appropriate termini,

the gene can be inserted into an expression vector, many of which are readily available today. See, for example, Maniatis et al., *Molecular Cloning, A Laboratory Manual*, CSH, Cold Spring Harbor Laboratory, 1982. Or, the region of the viral genome coding for the peptide can be cloned by conventional recombinant DNA techniques and expressed in procaryotic or eukaryotic expression systems to produce the desired peptides.

10 Preferably, the immunogen will be enriched for the desired epitopes to which antibody-producing B lymphocytes will respond by producing antibodies that will neutralize and inactivate essential steps in the life cycle of HIV infection. As used herein,
15 "enriched" means that a desired epitope constitutes at least 25% of the HIV protein, preferably at least 50%, and most preferably about 95%. More particularly, solutions containing disrupted virus lysate or extracts, or supernatant of biologically-expressed
20 recombinant proteins or disrupted expression vectors or proteins containing mimicked epitopes can be enriched for such proteins, as desired, using purification methods, such as, for example, polyacrylamide gel electrophoresis. Immunoaffinity purification is a
25 preferred and convenient method for purification of proteins and peptides containing the desired HIV epitopes, e.g., affinity purification using mono specific affinity purified polyclonal or monoclonal antibodies. The extent to which the peptides are
30 purified from the solutions for use as an immunogen can vary widely, i.e., from about 50%, typically at least 75% to 95%, desirably 95% to 99% and, most desirably, to absolute homogene.

 To obtain antibodies to the desired epitopes,
35 animals are immunized with either the peptides of

interest or HIV proteins containing them which have been treated to remove carbohydrates and HLA antigens as disclosed above. Immunization protocols are well known and can vary considerably yet remain effective.

- 5 See Colco, *Current Protocols in Immunology*, John Wiley and Sons, Inc. 1995. The proteins and/or peptides can be suspended or diluted in an appropriate physiological carrier for immunization. Suitable carriers are any biologically compatible, non-toxic substance to deliver
10 and/or enhance the immunogenicity of the peptides, including sterile water and 0.9% saline.

- Alternatively, the peptides can be coupled to a carrier molecule before being used as an immunogen. One preferred technique, for example, discussed in more
15 detail below, involves the attachment of the proteins and fragments thereof to multiple repeats of a glcopeptide, such as muramyl dipeptide (MDP), to form a microparticle, typically less than 1 micron, and preferably less than 0.2 microns, in diameter. The
20 microparticle then can be dispersed in a pharmaceutical carrier for injection. This procedure achieves a high density of the peptide which can be used to elicit the desired immune response. The selection of carrier will vary depending upon the route of administration and
25 response. The compositions can be sterilized by conventional, well-known sterilization techniques. The peptides can be administered by oral or parenteral routes, preferably the latter.

- Immunogenic amounts of antigenic preparations
30 enriched for the desired epitopes are injected, generally at concentrations in the range of 1 μ g to 20 mg/kg body weight of host. Administration can be by injection, e.g., intramuscularly, peritoneally, subcutaneously, intravenously, etc. Administration can

be one time or a plurality of times, usually at one to four week intervals.

Immunized animals are monitored for production of antibody to the desired epitope. High affinity
5 complement fixing IgG antibody is preferred for passive immunotherapy and can be used intact or as fragments such as Fv, Fab, F(ab')₂. Antibody fragments may be preferable when greater tissue penetration is desirable. Antibodies and fragments can be given alone
10 or as conjugates with toxic substances or isotopes. Once the desired antibody response is attained, blood is collected by, for example, venipuncture, cardiac puncture, or plasmapheresis. Antibodies are purified from the complex serum or plasma mixture in accordance
15 with conventional procedures, including, for example, salt precipitation, ion exchange chromatography, size chromatography, affinity chromatography. Oftentimes, a combination of methods is used. Immunoaffinity chromatography is a preferred method.

20 To circumvent possible antigenicity in a human receiving antibody derived from a non-human animal, recombinant antibodies can be constructed. One type of recombinant antibody is a chimeric antibody, wherein the antigen binding fragment of an immunoglobulin
25 molecule (variable region) is connected by a peptide linkage to at least part of another protein not recognized as foreign by humans, such as the constant portion of a human immunoglobulin molecule. This can be accomplished by fusing the animal variable region
30 exons with human kappa or gamma constant region exons. Various techniques are known to the skilled artisan, such as those described in PCT 86/01533, EP171496, and EP173494, the disclosures of which are incorporated herein by reference. A preferred type of recombinant
35 antibodies is CDR-grafted antibodies.

PHARMACEUTICAL FORMULATIONS AND THEIR USE

The antibodies of this invention that neutralize infectivity, kill infected CD4 lymphocytes and inactivate functionally important events in the life cycle of HIV are incorporated as components of pharmaceutical compositions. The compositions comprise a therapeutic or prophylactic amount of at least one of the antibodies of this invention, and desirably an antibody cocktail, with a pharmaceutically acceptable carrier. A pharmaceutically acceptable carrier is any compatible, non-toxic substance suitable for the delivery of the antibodies to the patient. Thus, this invention provides compositions for parenteral administration which comprise a solution of antibody dissolved in an acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers can be used, e.g., water, buffered water, 0.4% saline, 0.9% saline, 0.3% glycine and the like. These solutions are sterile and generally free of particulate matter. The compositions further can comprise pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, toxicity adjusting agents and the like. For example, sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate, etc., can be used. The concentration of antibody in these formulations can vary, typically from less than about 0.1 mg/ml to as much as 150 or 200 mg/ml, preferably between about 1 mg/ml and about 20 mg/ml, and will be selected primarily based on fluid volumes, viscosities, etc., preferably for the particular mode of administration selected. Determining the concentration of a particular antibody or antibody cocktail is within the abilities of one of ordinary skill in the art. Thus, a typical

pharmaceutical composition for intravenous infusion can be made up to contain 250 ml of sterile Ringer's solution and 100-200 mg of antibody. Compositions for intramuscular injection can be made up to contain 1 ml sterile buffered water and about 20 to about 50 mg of antibody. Actual methods for preparing parenterally administrable compositions will be known or apparent to those skilled in the art and are described in more detail in, for example, *Remington's Pharmaceutical Science*, 15th Ed., Mack Publishing Company, Easton, Pa. (1980), which is incorporated herein by reference. Such compositions can contain a single antibody which is, for example, specific for certain strains of HIV or for a single protein or glycoprotein expressed by most and, more preferably, all strains of HIV. Alternatively, a pharmaceutical composition can contain more than one antibody to form a "cocktail." For example, a cocktail containing antibodies against various proteins and strains of HIV would be a universal product with therapeutic or prophylactic activity against the great majority of the clinical isolates of HIV. The cocktail can contain antibodies which bind to epitopes on proteins or glycoproteins of the HIV envelope, for example, or can contain a combination of antibodies to epitope sites identified above on HIV_{1SF2} Env proteins gp160, gp120, and gp41; Gag protein p7, p17 and p24; reverse transcriptase heterodimer p66/55 and protease p10, or a subgroup thereof, thus neutralizing a series of epitopes crucial in the life cycle of HIV. Antibodies to epitope sites on other neutralizing or inactivating regions of HIV proteins also, of course, can be employed.

For example, antibodies which modify attachment, cell entry, transcription, translation, assembly, targeting of the mature virion to the plasma membrane

and extrusion of the virion will interfere with HIV life cycle events. Antibody cocktails will more frequently be employed to obtain inactivation of multiple essential HIV proteins. This will be of therapeutic benefit in particular within virions lack the outer envelope but possibly are infectious should they gain cell entry by other mechanisms such as micro-pinocytosis or transfection or the like. The molar ratio of the various antibody components usually will not differ by more than a factor of 10, more usually by not more than a factor of 5, and will usually be in a molar ratio of about 1:1-3 to each of the other antibody components.

With respect to antibodies to the nine specific peptides set forth above, a desirable antibody cocktail comprises antibodies to the two envelope gp120 peptides and gp41 peptide. More desirably, the cocktail comprises antibodies to those three epitope regions plus an antibody to the protease p10 epitope region. Even more desirably, the cocktail comprises antibodies to those four epitope regions plus antibodies to at least one of the other five enumerated epitope regions. In a most preferred embodiment, the cocktail comprises antibodies to all nine of the epitope regions.

The antibodies and antibody cocktails of the present invention can be administered independently or given in conjunction with other anti-retroviral agents. The current status of the development of other anti-retroviral agents, and of anti-HIV agents in particular, is reviewed in Mitsuya et al., *Nature* 325:773-778, 1987.

The antibodies and peptides of this invention can be stored in liquid format at various temperatures known to preserve antibody activity, e.g. -70°C, -40°C, -20°C, and 0-4°C or lyophilized for storage and

reconstituted in a suitable carrier prior to use. This technique has been shown to be effective with conventional immune globulins, purified antibodies, and immunogens composed of proteins, glycoproteins, and peptides. Art-known lyophilization and reconstitution techniques can be employed and it will be appreciated by those skilled in the art that lyophilization and reconstitution can lead to varying degrees of antibody activity loss (e.g., with conventional immune globulins, IgM antibodies tend to have greater activity loss than IgG antibodies) and that doses may have to be adjusted to compensate for any loss.

The compositions containing the present antibodies or cocktails thereof can be administered for the therapeutic and/or prophylactic treatment of HIV infections. In therapeutic application, compositions are administered to a patient already infected with HIV, in an amount sufficient to treat or at least partially arrest the infection and its complications. An amount adequate to accomplish this is defined as a "therapeutically effective dose." Amounts effective for this use will depend upon the severity of the infection and the general state of the patient's own immune system, but generally range from about 0.1 to about 200 mg of antibody per kilogram of body weight with dosages of from 0.5 to 25 mg per kilogram being preferred. The compositions of this invention can be employed in serious disease states that are life-threatening or potentially life-threatening situations. In such cases, it is possible and may be felt desirable by the treating physician to administer substantial excesses of these antibodies.

In prophylactic applications, compositions containing the present antibodies or a cocktail thereof are administered to a patient not already infected by

HIV, but perhaps recently exposed to or thought to have been exposed to, or at risk of being exposed to the virus (such as, for example, the newborn of an HIV infected individual), or immediately following an exposure or suspected exposure to HIV. If the composition is to be administered to an HIV-infected pregnant female, it can be given once or multiple times prior to delivery to reduce HIV infectivity in maternal blood and thereby reduce the risk of HIV transmission to the newborn. The newborn at risk also can be treated to further reduce the risk of contracting HIV. An amount defined to be a "prophylactically effective dose" generally ranges from 0.1 mg to 25 mg per kilogram of body weight, depending upon the patient's state of health and general level of immunity.

In addition, the antibodies of the present invention can find use as a target-specific carrier molecule. An antibody can be bound to a toxin to form an immunotoxin or a radioactive material or drug to form a radiopharmaceutical or pharmaceutical. Methods for producing immunotoxins and radiopharmaceuticals are well known (see, for example, *Cancer Treatment Reports* 68:317 (1984)). Heteroaggregates of antibodies of the present invention and human T-cell activators, such as monoclonal antibodies to the CD3 antigen or to the Fc gamma receptor on T-cells, can enable human T-cells or Fc-gamma bearing cells (such as K cells or neutrophils) to kill HIV infected cells via antibody dependent cell-mediated cytotoxicity (ADCC). Such heteroaggregates can be assembled, for example, by covalently cross-linking the anti-HIV antibodies to the anti-CD3 antibodies using the heterobifunctional reagent N-succinimidyl-3-(2-pyridyl dithiol)propionate, as described in Karpowsky et al., *J. Exp. Med.* 160:1686 (1984), which is incorporated by reference herein.

Other anti-HIV agents also can be included in the formulations, such as 3'-azido-3'-deoxythymidine, 2',3'-dideoxycytidine, 2',3'-dideoxy-2', 3'-didehydrocytidine, etc.

5 In addition to antibody compositions, compositions comprising the peptides of this invention can be administered for therapeutic and prophylactic vaccination of HIV-infected individuals. For therapeutic application, compositions comprising
10 peptides, either as isolated peptides optionally modified as discussed above or contained within HIV proteins treated as described above and desirably coupled to an MDP microparticle to further stimulate immunogenicity, are administered to a patient infected
15 with HIV. The amount of peptide administered is chosen so as to stimulate antibody production to functional HIV epitopes not previously recognized by the patient's immune system so that the stimulated antibodies can arrest the infection. In prophylactic applications,
20 compositions of the peptides coupled to the microparticle MDP are administered to persons not infected with HIV to stimulate the production of antibodies against otherwise unrecognized epitopes to provide a protective function against future infection.

25 DIAGNOSTIC AND PROGNOSTIC USES
OF ANTIBODIES AND ANTIGEN

The antibodies and epitopes recognized by them and disclosed in the present invention also are useful for the diagnosis and management of HIV infection.
30 Typically, diagnostic assays employing antibodies and/or their respective antigens entail the detection of the antigen-antibody complex. Numerous immunoassay configurations have been described and employ either labeled or unlabeled immunochemicals for this purpose.

When unlabeled, the antibodies find use, for example, in agglutination assays, antibody dependent complement mediated cytolysis assays, and neutralization assays. Unlabeled antibodies can be used in combination with other, labeled, antibodies (second antibodies) that are reactive with the primary antibody, such as antibodies specific for immunoglobulin. Unlabeled antibodies can be used in combination with a labeled antibody which is reactive with a non-competitive epitope on the same antigen, such as in sandwich type immunoassays, or in combination with a labeled antigen. Alternatively, the antibodies can be directly labeled and used in both competitive and non-competitive immunoassays. These assay types and configurations are well known in the art. A wide variety of labels can be employed, such as radioisotopes, fluorescent tags, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, ligands (particularly haptens), etc. Numerous types of immunoassays are available and, by way of example, include those described in U.S. Pat. Nos. 3,817,827; 3,850,752; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; and 4,098,876.

Commonly, the antibodies and peptides of the present invention are utilized in enzyme immunoassays, where, for example, the subject antibodies, or their respective antigens are conjugated to an enzyme and the immunoassay is configured to provide maximal sensitivity and specificity in detecting HIV antigens in biological samples such as human blood serum, saliva, semen, vaginal secretions or viral infected cell culture suspension.

Kits also can be designed for use with the subject antibodies for use in the detection of HIV infection or the presence of HIV antigen. The kits comprise antibodies of the present invention optionally in

conjunction with additional antibodies specific for other epitopes of HIV. The antibodies, which can be conjugated to a label, unconjugated or bound to a solid support such as the surface of a microtiter plate well or a polystyrene bead, are included in the kits with buffers, such as Tris, phosphate, carbonate, etc., stabilizers, biocides, inert proteins, e.g., bovine serum albumin, or the like. Generally, these materials will be present in less than about 5% wt. based on the amount of active antibody, and usually present in total amount of at least about 0.001% wt. based again on the antibody concentration. Frequently, it will be desirable to include an inert extender or excipient to dilute the active ingredients, where the excipient can be present in from about 1% to 99% wt. of the total composition. Where a second antibody capable of binding to the antibody is employed, the second antibody usually will be present in a separate vial. The second antibody typically is conjugated to a label and formulated in an analogous manner with the antibody formulations described above. The subject epitope recognized by the antibody can be provided labeled or non-labeled and can be provided as part of a larger protein (synthetic, recombinant, or native), with or without modification such as the addition of spacer arms, amino groups, or cysteine residues, which can be used to attach the peptide to a support and extend it from the surface of the support. Such modifications are employed to provide the epitope in an arrangement to optimize immunoreactivity with the antibody. Such peptides are formulated in a manner analogous to that of the epitope-containing proteins as described above.

The detection of HIV antigens, or the whole virus, in various biological samples is useful in diagnosing a current infection by HIV, evaluating

response to therapy, enumerating infected cells, serotyping HIV strains (clades), identifying and quantitating virulence factors associated with primary infection, progression and complications such as peripheral neuropathy, multi focal leukoencephalopathy, and Kaposi's sarcoma. Biological samples can include, but are not limited to, blood, serum, saliva, semen, tissue biopsy samples (brain, skin, lymph nodes, spleen, etc.), cell culture supernatants, disrupted eukaryotic and bacterial expression systems, and the like. Presence of virus, viral antigens, virulence factors, and serotyping determinants are tested for by incubating the antibody with the biological sample under conditions conducive to immune complex formation, followed by the detection of complex formation. In one embodiment, complex formation is detected through use of a second antibody capable of binding to the primary antibody and typically conjugated to a label. The second antibody is formulated in a manner analogous to that described for the primary antibody formulations described above. In another embodiment, the antibody is attached to a solid phase support which then is contacted with a biological sample. Following an incubation step, labeled antibody is added to detect the bound antigen. In another embodiment, the antibody is conjugated to a detection label and following an incubation step with a biological sample, such as cells or tissue sections, the sample is evaluated by flow cytometry or microscopy for the antigen.

30 PREPARATION AND USE OF SYNTHETIC PEPTIDES

Peptides of this invention can be modified by introducing amino acid substitutions into the peptide. Substitutions may be desirable to vary one or more particular amino acids to more effectively mimic the

epitopes of the different retroviral strains or to enhance immunological responses or MHC interactions with the epitope resulting in greater immunogenicity of the mimicked epitope when used for immunization or vaccination. In addition, it can be desirable to make certain amino acid substitutions to enhance the chemical stability of the peptide.

More specifically, a polypeptide employed in the subject invention need not be identical to any particular HIV polypeptide sequence, so long as it is able to provide immunological competition with proteins of at least one of the strains of HIV. Therefore, the subject polypeptides can be subject to various changes, such as insertions, deletions, and substitutions, either conservative or non-conservative, where such changes will enhance the desired activity of the peptide. Conservative substitutions are substitutions with similar amino acids within a group such as neutral, acidic, basic, and hydrophobic amino acids. Examples of substitutions within such groups would include gly, ala; val, ile, leu; asp, glu; asn, gln; ser, thr; lys, arg; phe, tyr; and nor, met. Additional amino acid substitutions, obtained by application of molecular modelling software to HLA allotyping database classification (DNA and serological), are shown:

	Group, 1 letter code	Group, 3-letter code
	F, S	phe, ser
	Q, R	gln, arg
	K, N	lys, asn
5	E, G	glu, gly
	G, R	gly, arg
	H, Q	his, gln
	I, T	ile, thr
	V, A	val, ala
10	D, N	asp, asn
	Y, F	tyr, phe
	I, F	ile, phe
	K, E	lys, glu
	E, L, R	glu, leu, arg
15	Y, L	tyr, leu
	S, V	ser, val
	Y, N, F, D	tyr, asn, phe, asp
	D, R	asp, arg
20	L, F	leu, phe

In a preferred embodiment of the invention, amino acid modifications are made so as to substitute hydrophilic residues on the more hydrophilic end of the peptide of interest and hydrophobic residues on the more hydrophobic end of the peptide. Such substitutions result in the formation of an amphipathic helix with the desired epitope bracketed between the substitutions. Substituted amino acids in the D isomer can be employed to bracket epitopes to protect and stabilize the epitope and enhance immunogenicity of the epitope. Since D-amino acids are not cleaved by

intracellular enzymes, such portion provides peptide epitopes of the desired length for interaction with MHC molecules when they are inserted at appropriate sites. This is described in detail in Example 8.5 below.

5 Usually, the modified sequence will not differ by more than about 20% from the sequence of at least one strain of the human immunodeficiency retrovirus except where additional amino acids are added at one or both termini for the purpose of providing an "arm" by which
10 the peptide of this invention conveniently can be immobilized on solid phase supports, attached to macro molecules or modified to enhance immunogenicity by altering or enhancing MHC binding and presentation. The arms can comprise a single amino acid or as many as
15 50 or more amino acids, and typically are 1 to 10 amino acids, in length.

 Amino acids such as tyrosine, cysteine, lysine, glutamic or aspartic acid, or the like can be introduced at the C-or N-terminus of the peptide or
20 oligopeptide to provide for a useful functionality for linking. Cysteine is particularly preferred to facilitate covalent coupling to other peptides or to form polymers by oxidation.

 Additionally, the peptide or oligopeptide
25 sequences can differ from the natural sequence by the sequence being modified by terminal- NH_2 acylation (e.g., acetylation), thioglycolic acid amidation, or terminal carboxy amidation (e.g., with ammonia or methylamine), to provide stability, increased
30 hydrophobicity for linking or binding to a support or other molecule, or for polymerization.

 Thus, for example, in a preferred embodiment of the peptides disclosed herein, one or more cysteine
35 residues or a combination of one or more cysteine residues with spacer amino acids can be added to the

termini of the peptide. Glycine is a particularly preferred spacer when individual peptides are desired. When multiple peptide repeats of the peptide are desired, the peptide is synthesized off of a lysine core to form a tetravalent peptide repeat. The configuration is shown by way of example. Preferred peptides for use in oxidative polymerization are those in which at least two cysteine residues are added to the termini of a desired peptide. When two cysteine residues are present at the same end of the peptide, a preferred embodiment exists when the cysteine residues are separated by one to three spacer amino acid residues, preferably glycine. The presence of cysteine residues may allow the formation of dimers of the peptide and/or increase the hydrophobicity of the resulting peptide which facilitates immobilization of the peptide in solid phase or immobilized assay systems. Of particular interest is the use of the mercapto group of cysteines or thioglycolic acids used for acylating terminal amino groups or as the first amino acid for building multiple peptide repeats or the like for linking two of the peptides or oligopeptides or combinations thereof by a disulfide linkage or a longer linkage to form polymers that contain a number of epitopes. Such polymers have the advantage of increased immunological reaction. Where different peptides are desired for immunization, they are individually assembled and combined in a cocktail to provide the additional ability to induce antibodies that immunoreact with several antigenic determinants of different HIV isolates. To achieve the formation of antigenic polymers (synthetic multimers), compounds can be employed having bis-haloacetyl groups, nitroarylhalides, or the like, where the reagents are specific for these groups. The linking between the one

or two mercapto groups of the peptides or oligopeptides can be a single bond or a linking group of at least 2 or more carbon atoms.

LINKING PEPTIDES TO MACROMOLECULAR CARRIERS

5 The subject peptide can be employed linked to a soluble macromolecular (e.g., not less than 5 kDal) carrier. Conveniently, the carrier can be a poly(amino acid), either naturally occurring or synthetic, to which antibodies are unlikely to be encountered in
10 human serum. Examples of such carriers are poly-L-lysine, keyhole limpet hemocyanin, thyroglobulin, albumins, such as bovine serum albumin, tetanus toxoid, etc. The choice of the carrier is
15 primarily dependent upon the ultimate use intended for the antigen and one of convenience and availability. In a preferred embodiment, the carrier comprises multiple repeats of glycopeptide a microparticle which can be synthesized or isolated from certain bacteria
20 such as *Propionibacterium acini* or the like. This microparticle is composed of muramyl dipeptide extensively crosslinked resulting in multimeric configurations.

 When muramyl dipeptide is isolated from *Propionibacterium acini* or related organisms, strain
25 selection is helpful, and selection is based on chemical analysis of the bacterial cell wall. The preferred embodiment is muramyl dipeptide extensively crosslinked with a dipeptide composed of L-alanine-D-isoglutamine.

30 From preliminary experiments, strain differences have been identified in which dipeptide composition and peptide length vary. Isolates with high concentrations of lipid A and O-acylated beta myristate are components of the cell wall. Preliminary experiments showed these

differences are associated with increases in toxicity and decreases in adjuvant effect. Strain selection and the purification of the preferred embodiment is discussed by way of Example 4, below.

5 The MDP microparticle can be synthesized by employing procedures known in the art. It has been well established that MDP is a potent immunostimulant but has significant toxicity. Many attempts to reduce MDP toxicity have employed procedures to delay release,
10 such as MDP incorporation into liposomes or other related compounds or modification of terminal groups. Chemical modification resulted in marked reduction in the desired adjuvant effect, and designs which change delivery rate have been difficult to control. By way
15 of example, MDP microparticle configuration, size parameters, and antigen delivery attachment methods are provided below. Removal of lipids from the microparticle configuration facilitates rapid internalization of MDP by antigen presenting cells
20 (APC). Antigen presenting cells are predominately of monocytes lineage and include monocytes, macrophage, Histiocytes, Kuffer cells, Dendritic cells, Langerhans cells, etc. and participate in antigen processing and antigen presentation through MHC associated events.
25 Factors which contribute to the development of immune responses to foreign protein can be, in part, determined by amino acid sequence and sequence susceptible to protease cleavage in the micro environment. Successful immune responses are most
30 frequently observed to peptides which form an amphipathic helix with a hydrophobic terminus, preferably on the amino terminal end, and hydrophilic amino acids most frequently on the carboxyl terminal end. Sequence configurations that are resistant to
35 protease degradation and form amphipathic helix

arrangements are frequently strong immunogens. Residues which contain proline in the sequence are generally poorly immunogenic by preventing helix formation and glycosylation sites are less favorable and frequently inhibit responses directed at peptide epitopes. Antigen challenge which results in a successful immunological response in the host animal requires antigen processing and presentation of antigen through MHC associated events. Exogenous antigen is primarily processed by antigen presenting cells (APC) after internalization into endosomes. Following proteolysis by enzymes, such as cathepsin D, which are present and react in this acid environment, peptide fragments which satisfy the criteria described above are assembled with MHC class II and presented on the cell surface. When peptides are presented in sufficient density immune events result. The type of immune response is driven by the density of peptide per APC, micro-environment, the cytokine environment, and the lymphocyte type initially stimulated by antigen presenting cells. Following internalization, a cascade of cytokine responses is induced which modifies the micro-environment and establishes conditions conducive of immunological events.

By way of example, a unique MDP microparticle (0.01 - 0.2 micron) is used to deliver immunogen to antigen presenting cells resulting in immune responses to poorly immunogenic epitopes not observed using conventional methods as shown in Example 5 below. Quantitation of these immune responses demonstrate 10 to 100 fold increases in antibody concentration as compared to other adjuvants.

Subject peptides employed as immunogen can be linked to the carboxyl terminal amino acid moiety of muramyl dipeptide using either the amino or carboxyl

terminus of the subject peptide or to the aldehyde oxidation product of the carbohydrate moiety as disclosed in the examples. There will be at least one molecule of the subject peptide per MDP microparticle, preferably 10-100 molecules of subject peptide per MDP microparticle and most preferably 100 to 1000 subject peptides per MDP microparticle. Carrier size and available linkage groups, therefore, will influence the number of subject peptides per carrier.

Macro-carrier composition affects immunogenicity by influencing preferential cell uptake, peptide half-life, and antigen presentation through MHC immunological events. One or more different subject peptides can be linked to the same macro-carrier but preferably a single subject peptide is attached either in the univalent or tetravalent configuration to the macro-carrier. When immunization with more than one subject peptide is desired, a cocktail of subject peptide macro-carrier conjugates can be prepared by mixing individual conjugates at ratios to optimize immunogenicity of each subject peptide introduced in the cocktail. In this configuration sufficient peptide is available on each macro-carrier conjugate (100-1000 peptides) to enhance antigen presentation by a single antigen presenting cell. Immunogenicity of the subject peptide will be optimized by adjusting both the number of subject peptides per macromolecular carrier, presentation configuration, such as amino versus carboxyl attachment, terminal amino acid modification, and space arm length and composition, as disclosed. In this configuration, antigen processing by the antigen presenting cell results in a high density, usually more than 100 and most frequently more than 500 peptides, presented at the cell surface of the antigen presenting cell through MHC interactions. With this

configuration significantly higher concentrations of antibody are produced, following immunization, as shown in the examples below.

The manner of linking is conventional, employing such reagents as p-maleimidobenzoic acid, p-methyldithiobenzoic acid, maleic acid anhydride, succinic acid anhydride, glutaraldehyde, etc. The linkage can be made at the N-terminus, C-terminus, or at a site intermediate to the ends of the molecule. With multiple repeats of muramyl dipeptide, attachment of the subject peptide to aldehyde groups produced by the mild oxidation of sugar residues with, for example, sodium periodate following mild reduction with sodium borohydride and the like, the Schiff's base intermediate is converted to a stable covalent linkage. The number of peptides per microparticle can be controlled by varying oxidation conditions and quantitated by employing a radioactive tracer. These methods are well known in the art. The method of attachment and attachment configuration can vary from peptide to peptide as needed to achieve the desired response.

Various assay protocols familiar to those skilled in the art can be employed for detecting the presence of either antibodies to retroviral protein epitopes or detecting retroviral proteins in complex protein mixtures. Of particular interest is a novel assay herein disclosed in which the subject peptide is covalently attached to a detection label such as horseradish peroxidase and the native HIV protein expressing epitope or epitopes is either directly or indirectly attached to a solid phase support. In this configuration an antibody which recognizes the peptide epitope will bridge the epitope on the solid phase with the epitope on the label. With this method the epitope

reactivity of an antibody to HIV can be determined and quantitated by varying the peptides attached to the label. Peptide epitopes which are associated with HIV serotype, virulence factors or other HIV

5 characteristics can be identified and measured in any sample expressing these epitopes by a one step competitive immunoassay herein disclosed and provided by way of example.

10 Use of Antibodies and Their Respective Epitopes In Immunoaffinity Purification Procedures

Antibodies specific for epitopes contained within HIV proteins and purified proteins containing these epitopes are of particular advantage for use in immunoaffinity purification of proteins and peptides
15 containing these epitopes and antibodies reactive with them. Generally, the antibodies will have affinity association constants on the order of 10^8 to 10^{12} M. Such antibodies can be used to purify proteins and peptides containing the epitopes of interest.
20 Oftentimes, genetically modified bacteria can be used to make HIV proteins, and the recombinant fusion proteins of interest can be purified from the culture medium of the recombinant expression system if the expressed protein is secreted, or from the components
25 of the disrupted biological expression system if it is not secreted, or from complex biological mixtures of proteins of which some or one component contains the epitope mimicking an epitope on HIV. Generally, the antibodies which are capable of reacting with HIV
30 epitopes are attached to or immobilized on a substrate or support. The solution containing the epitopes then is contacted with the immobilized antibody under conditions suitable for the formation of immune

complexes between the antibody and the protein containing the epitope. Unbound material is separated from the bound immune complexes, and the bound proteins are released from the immobilized antibody and recovered in the eluate.

Similarly, proteins or peptides containing epitopes of HIV or mimicking epitopes of HIV can be attached to or immobilized on a substrate or support and used to isolate antibodies of interest from a solution. A solution containing the antibodies, such as plasma from which albumin has been removed, is passed through a column of immobilized peptides or proteins containing the desired epitopes and, following immune complex formation, non-reactive antibody is separated from the bound immune complex and the antibody is released with an elution buffer and recovered in the eluate. This is of particular value in purifying protein containing epitopes mimicking epitopes of HIV but derived from sources phylogenetically unrelated to HIV.

Typically, antibodies are crudely purified from hyperimmune sera. Ascites fluid or cell culture supernatants and proteins or peptides containing epitopes mimicking HIV epitopes will be crudely purified from biological sources such as, but not limited to, body fluids, blood, blood components, cell extracts, tissue extracts of both adult and embryonic origins, and culture supernatants, extracts of cultured cells, venoms, and recombinant fusion products prior to attachment to a support. Such procedures are well known by those skilled in the art and may include fractionation with neutral salts at high concentration. Other purification methods, such as ion exchange chromatography, gel filtration chromatography, preparative gel electrophoresis, or affinity

chromatography, also can be used to increase the purity of the preparation prior to its use as an immunoabsorbant. Affinity purified antibody can be prepared when desired by reacting crudely purified antibody preparations with a support matrix to which the reactive epitope or protein containing the epitope has been attached.

Of particular interest are antibodies to HIV epitopes phylogenetically mimicked through nature.

Such antibodies are useful as therapeutic agents and also are useful for studying HIV by allowing purification of HIV proteins and the mapping of HIV proteins for sequence location and function. Such antibodies can be produced by immunization with HIV proteins/peptides derived from HIV and immunoaffinity purified by reacting the resultant hyperimmune polyclonal multivalent antisera with proteins/peptides derived from non-HIV sources such as embryonic proteins, venoms, and non-HIV microbial/viral components immobilized on a support as discussed above. The resulting immunoaffinity purified antibody is epitope specific for an epitope or epitopes shared by HIV and the phylogenetically unrelated protein used for its immunopurification. These epitope specific antibodies have particular utility in the immunoaffinity purification of proteins and peptides of both HIV and non-HIV origin. Such antibodies can be used to map the location of the epitope on HIV to determine its sequence, evaluate functional importance in the life cycle of HIV, its distribution within the clades of HIV and among other retroviridae, its association with HIV virulence, and, when non-toxic to man but neutralizing a crucial function in the life cycle of HIV, used to treat HIV infection.

The support to which the antibodies or epitopes are immobilized desirably has the following general characteristics: (a) weak interactions with proteins in general to minimize non-specific binding, (b) good flow characteristics which allow the flow through of high molecular weight materials, (c) possession of chemical groups that can be activated or modified to allow chemical linkage of the antibody or epitope, (d) physical and chemical stability in the conditions used to link the antibody, and (e) stability to the conditions and constituents of the buffers required for absorption and elution of the antigen. Some supports commonly used are agarose, derivatized polystyrenes, polysaccharides, polyacrylamide beads, activated cellulose, glass and the like. Various chemical methods exist for the attachment of antibodies and antigens to substrate supports. See generally, Cuatrecasas, P., *Advances in Enzymology* 36:29 (1972). The antibodies and antigens of the present invention can be attached directly to the support or, alternatively, through a linker or spacer arm. General conditions required for immobilization of antibody and antigens to chromatographic supports are well known in the art. See, for example, Tijssen, P., 1985, *Practice and Theory of Enzyme Immunoassay*, which is incorporated herein by reference. Actual coupling procedures will depend slightly on the characteristics and type of the antibody or the antigen to be coupled. Attachment typically occurs through covalent bonds.

An immune serum, ascites fluid or culture supernatant rich in antibody or extract or lysate of HIV virus, the supernatant or extract from a cultured biological expression system, the supernatant or extract from a suspension of the disrupted cells tissue or blood component (adult and embryonic) or other

complex protein mixtures such as venoms, body fluids, or culture products containing the epitope then is added to the appropriate separation matrix. The mixture is incubated under conditions and for a time
5 sufficient for antigen-antibody attachment to occur, usually at least 30 minutes, more usually 2 to 24 hours. The immobilized immune complexes containing the specifically bound antibody or epitopes then are separated from the complex mixture and extensively
10 washed with absorption buffer to remove non-bound contaminants. The immune complexes then can be dissociated with an elution buffer compatible with the particular support, the attached protein, and the eluate protein. The elutable protein, antigen, or
15 antibody is recovered in the eluate. Elution buffers and techniques are well known by those skilled in the art. Peptides that contain the epitope recognized by the antibody can be used in the elution buffer to compete for the antibody binding site and elutions can
20 be performed under mild elution conditions. The selectively absorbed protein can be eluted from the affinity absorbent by altering the pH and/or ionic strength of the buffer or with chaotropic agents. The selection of an elution buffer, its concentration and
25 other eluting conditions are dependent on the characteristics of the antibody-antigen interaction, and once determined should not be subject to significant change.

The eluted protein may require adjustment to a
30 physiologic pH and ionic strength if low or high pH or ionic strength buffers or chaotropic agents are used to dissociate the immune complex. Such adjustment can be made by dialysis or gel filtration chromatography. These methods also permit the eluted protein to regain
35 its native conformation.

The foregoing methods yield, e.g., substantially purified proteins containing epitopes of, or mimicking epitopes of, HIV and antibodies reactive with the epitopes. The purified proteins typically will be
5 greater than 50% pure, more usually at least 75% pure, and frequently greater than 95% to 99% pure.

Other features and advantages of the present invention will become apparent from the following experimental descriptions, which describe the invention
10 by way of example. The examples further illustrate the process of this invention but are not meant to limit the invention in any way.

Example 1

Preparation of Human Anti-HIV Antibody (IgG fraction)
15 Pools For Use In Mapping HIV Epitope Differences Between Man and Goat Immune Reactions

Human sera from HIV-infected patients were obtained from a community health clinic with patient permission, patient signed informed consent, physician
20 approval and local IRB approval. All sera were initially screened for HIV reactivity at a dilution of 1:10 employing a commercially available test kit from Abbott Laboratories. Sera with high reactivity (arbitrarily defined by test result absorbances
25 greater than 1) were further evaluated by Western Blot analysis to identify those sera with antibody reactivities to most HIV proteins (env, gag and pol). Patient sera that demonstrated good reactivity to most HIV proteins as defined were further evaluated by
30 microculture neutralization assays to identify the sera-containing antibody specificities which would neutralize HIV infectivity in microculture assays (total culturable infectious dose (TCID₅₀))

neutralization). Twenty-nine patients' sera with high antibody titer reactivity to gp160, gp120, p66/55, gp41, p24, and p17 and p10, and neutralized HIV infectivity in microculture were identified and pooled (20-40 ml each). Further evaluation of the pooled anti-human HIV revealed broad neutralization activity against multiple strains of HIV and high titer antibody (positive by Western Blot 1:100 or greater) to the nine epitope regions described in detail above. Human IgG was purified from this serum pool employing conventional procedures. Following purification the total IgG concentration was adjusted to 10 mg/ml, its composition and purity was evaluated by standard immunoassay procedures. The results demonstrated a purity of greater than 98% and a composition of human IgG. The purified human anti-HIV was divided into aliquots and frozen for subsequent use in experiments and procedures disclosed below. Those skilled in the art will be familiar with methods for characterizing both antigen and antibody pools to define specificities which may be used in subsequent determinations against unknown antibodies or antigens for comparative purposes.

As described in the following examples, this human anti-HIV was employed to follow the purification of HIV proteins from crude viral lysates and map HIV epitopes recognized by the human immune system and in competitive EIA to identify HIV epitopes targeted by antibodies produced in goats but not man. Western Blot analysis was employed to characterize antibody responses in goats immunized with either purified HIV proteins containing peptides of interest or synthetic versions of those peptides, and to evaluate the efficacy of a microparticle carrier complex designed to amplify immune responses to poorly immunogenic

peptides. Antibodies which neutralized HIV infectivity were evaluated by a microculture procedure which employed purified human CD4 lymphocytes isolated from peripheral blood mononuclear cells (PBMC),
5 employing standard techniques which use monoclonal antibody-conjugated magnetic particles to remove unwanted cells. CD4 lymphocytes were stimulated with mitogen to increase their susceptibility to HIV infection and were used throughout unless otherwise
10 noted as the host target for HIV infection. HIV_{1SF2} was employed throughout unless otherwise noted as the reference HIV strain. The effect of antibody on HIV infectivity was determined by microculture using techniques familiar to those skilled in the art.
15 Infectivity is expressed as infectious units (IU). Antibody mediated reductions in IU were associated with neutralization of virus infectivity and expressed as change in infectious unit. The human anti-HIV pool was used throughout all experiments described herein that
20 required human anti-HIV antibody. This human IgG anti-HIV pool was compared to several commercially available human anti-HIV preparations and had equal or greater HIV neutralizing activity and, when compared by Western Blot analysis, was significantly more reactive.

25

Example 2

Characterization of Commercially Available HIV Viral Lysates Employed Herein

Preliminary Studies

30 HIV_{1MN}, HIV_{1BAL} and HIV_{2NZ} were purchased from Advanced Bio-Technology, Inc., Columbia, MD, in the form of purified viral lysates. Analysis of these

purified viral lysates demonstrated lot to lot variation in total protein content with a range of 0.8 mg/ml to 1.2 mg/ml. The protein composition of each HIV lysate was evaluated by SDS-PAGE and Western Blot analysis with human IgG anti-HIV. The HIV lysates were treated with protease inhibitors and nonionic detergents (1.0% v/v), such as Nonidet P-40 or Igepal CA630, to fully dissociate HIV proteins and glycoproteins into their monomeric forms, and clarified by filtration through a 0.22 micron filter. Lipids were removed with SeroClear employing standard procedures. It is well known to those skilled in the art that HIV incorporates human proteins into its envelope as part of the budding process. Such contaminants once identified were removed by immunoaffinity chromatography. In the initial purification step serum contaminants present in growth media added to facilitate cell growth and contaminants in the HIV lysate were removed by immunoaffinity chromatography employing anti-normal human serum Sepharose CL6B (2-3mg antibody/gram Sepharose). Chromatography of HIV lysates were conducted at a matrix to lysate ratio of 1:1 volume/volume at a flow rate of 10 ml/hour. The chromatography and elution were monitored spectrophotometrically at a wave length of 280nm. The protein rich non-binding fraction containing the HIV related proteins was concentrated to 1 mg protein/ml and stored at -70°C for future use as needed. Proteins bound by the affinity matrices were eluted with glycine-HCl buffer pH 2.2 in 0.9% NaCl. Eluates were neutralized, dialyzed in PBS pH 7.8 containing 0.1% Igepal CA630, concentrated and stored at -70°C for future analysis. SDS-PAGE with Western Blot analysis of purified HIV preparations consistently demonstrated the presence of gp160, gp120, p66/55,

gp41, p10, p24, p17 and p7, employing human anti-HIV IgG. HIV proteins were not detected in glycine HCl eluate employing Western Blot analysis, but SDS-PAGE gels stained with coomassie brilliant blue for protein visualization demonstrated 2-3 weakly stained bands.

Characterization of Anti-HIV Antibody Produced to Partially Purified HIV Lysates

Goats (n=2) were immunized with the purified HIV proteins obtained above and responded immunologically with antibodies which reacted with immunodominant epitopes on HIV. Further evaluation of this antiserum demonstrated the presence of cytotoxic antibodies which reacted with both HIV-infected and non-infected CD4⁺ lymphocytes, and red blood cell (RBC) agglutinins were detected. These agglutinins were reacted with all human RBC blood groups and RBC's from rabbits and guinea pigs. Two possibilities for these unwanted antibody specificities were considered. One possibility was contamination from HIV lysates with proteins of cell culture origin, and the second was mimicry between HIV proteins/glycoproteins and glycoproteins found in man and other animal species. It is well known that host membrane proteins are often identified in the envelope of HIV. The incorporation of host membrane components into the envelope of HIV is thought to be non-specific and associated with the budding of the mature virion. Two such proteins previously identified in mature virion envelope are human HLA class I and class II antigens. Both HLA class I and class II antigens were quantitated employing an enzyme linked immunoassay and results demonstrated the presence of both HLA class I and class II antigens in these HIV preparations and at concentrations disproportionate to their concentration

measured in cell membrane preparations derived from uninfected culture cells. Further studies confirmed the presence of HLA class I and class II antigens in different preparations (n=17) of HIV viral lysate. The measured concentration in these preparations was variable but consistently 10 to 100 times greater than that measured in membrane extracts from uninfected control cells. The goat anti-HIV antibody was tested by Western Blot Analysis against known HLA class I and class II isolates and confirmed to contain antibody specificities directed against HLA class I, HLA class II (alpha and beta chain) and beta 2 microglobulin. This antibody was evaluated for HLA allotype specificity. Commercial trays containing lymphocytes of known allotypes were employed as targets. Under assay conditions, this antibody was cytotoxic to all lymphocytes, and this cytotoxicity was partially inhibited with soluble HLA class I and HLA class II in a dose dependent manner. (Table 2.1).

TABLE 2.1

HLA Class I Inhibition of Lymphocytotoxicity
in Antiserum Produced to Purified HIV Lysates

	Dilution	Anti-HIV	Anti-HIV & HLA I&II 25 ug	Anti-HIV & HLA I&II 50 ug	Anti-HIV & HLA I&II 100 ug	Anti-HIV & HLA I&II 200 ug	Pre- Immune Serum
5	u	8	8	8	8	8	0
	1:5	8	8	8	8	8	0
	1:10	8	8	4	4	4	0
	1:20	8	8	4	4	4	0
	1:40	8	8	4	4	4	0
10	1:80	8	4	2	4	2	0
	1:160	8	4	0	2	0	0
	1:320	8	2	0	0	0	0
	1:640	8	0	0	0	0	0
	1:1280	4	0	0	0	0	0

- 15 Soluble HLA class I&II was added to micro titer wells containing anti HIV antibody and incubated overnight at 4°C. Soluble HLA I&II reduced lymphocytotoxicity but had no additional effect at concentrations above 50ug.

- 20 Further studies demonstrated an antibody that, reacted with a phylogenetically preserved carbohydrate antigen present on gp120, human red and white blood cells, and red blood cells from different animals including rabbit, rat, and guinea pig. Absorption studies with human and rabbit red cells completely removed the remaining antibody activity to both RBC's (Table 2.2) and lymphocytes (Table 2.3) following absorption with S-HLA-I & II.

TABLE 2.2

Analysis of Anti RBC Absorbed Anti-HIV Antibody
for RBC Agglutinins Cells

RBC Absorption #	Anti* HIV1			Anti* HIV2			Anti* HIV1&2		
	AB+	O+	rabbit	AB+	O+	rabbit	AB+	O+	rabbit
0	256	256	256	256	128	128	128	256	128
1	128	128	128	128	64	128	64	128	128
2	32	32	32	32	32	64	32	32	32
3	8	4	4	4	4	4	8	4	4
4	2	--	--	--	--	--	2	--	--

*Antisera produced to purified HIV lysate resulted in RBC agglutinins produced in goats following immunization. Goats (n=2 each) were immunized with HIV1_{MN} and HIV1_{BAL} and/or HIV2_{N2}, respectively.

TABLE 2.3

Analysis of Anti RBC Absorbed Anti-HIV Antibody
for Lymphocytotoxicity During Immunization

RBC Absorption (n) #	Anti* HIV1			Anti* HIV2			Anti* HIV1&2		
	AB+	O+	rabbit	AB+	O+	rabbit	AB+	O+	rabbit
0	512	512	256	1024	1024	1024	512	1024	1024
1	256	256	256	256	512	512	256	256	256
2	128	64	128	64	64	128	64	128	64
3	32	16	16	16	16	32	16	16	16
4	4	4	4	4	4	4	4	4	4
5	2	2	2	±	2	2	2	2	2

*Antisera produced to HIV without glycosidase treatment at 20 week blood collection date and absorbed 0-5 times with red blood cells and tested against lymphocytes for lymphocytotoxicity.

Following the absorption and removal of antibody specificities to HLA and hemoagglutinins the goat anti-HIV antibody was identified to contain specificities similar to those previously described in the literature. This information demonstrated the need for modification of the HIV proteins to remove carbohydrate and HLA antigens to avoid the generation of cytotoxic antibodies directed against human antigens.

Example 3

10 Purification and HLA Class I and Class II Antigen Removal and Carbohydrate Removal of HIV Protein Isolated from HIV Lysates

HIV lysates of HIV_{1MN}, HIV_{1BAL} and HIV_{2NZ} were purchased from Advanced Biotechnologies, Columbia, MD. They contained protein concentrations in the range 0.8 - 1.2 mg protein/ml. Protease inhibitors were added to protect the proteins from degradation, and non-ionic detergent (Igepal Ca-630, or Nonidet P-40) was added to dissociate HIV proteins. The mixture was dispensed into capped extraction tubes with a delipidating reagent to remove lipids and clarify the mixture. Lipids were differentially dissolved in the organic layer after centrifugation and the aqueous phase was removed.

25 Contaminants of cell culture origin, including HLA, were removed by immunoaffinity chromatography on five separate affinity matrices prepared by the covalent attachment of: immunoaffinity purified polyclonal IgG antibodies to human serum proteins, monoclonal IgG antibody to HLA-1, monoclonal IgG antibody to HLA-2, monoclonal antibody to β 2-microglobulin, immunoaffinity purified polyclonal IgG antibodies to lymphocyte and red blood cell membrane antigens. Each matrix contained 2-3 mg antibody per g

Sepharose CL6B. Columns were configured in a tandem arrangement, and matrices were poured and equilibrated with PBS at pH 7.8 containing 0.1% Igepal Ca-630. Lysate solutions in volume equivalent to column bed volume were successively chromatographed through each column at a flowrate of 10 ml/h. The chromatography and elution were monitored spectrophotometrically at a wavelength of 280 nm. The protein-rich non-binding fraction containing the HIV related proteins were concentrated to 1 mg protein/ml.

SDS was added to the immunoaffinity-purified mixture containing the HIV proteins of interest and the mixture was heated at 70 °C for 10 minutes. The protein were enzymatically deglycosylated using PGNase. The protein mixture was fractionated by size chromatography on Sepharose G50 pre-equilibrated with saline containing 0.1% non-ionic detergent. Protein fractions were collected and those containing the desired HIV proteins were individually pooled. The three protein pools, individually enriched for gp160 and gp120, p66/55 and gp41, and p24, p17 and p10 were retained. Fractions were stored at -70 °C until further processing.

Detailed methods for quantitation and removal of human leukocyte antigen (HLA) are disclosed in "Identification, Characterisation, and Quantitation of Soluble HLA Antigens in Circulation and Peritoneal Dialysate of Renal Patients", F. Gelder, *Annals of Surgery* Vol. 213, (1991), incorporated herein by reference.

Table 3.1 shows data obtained from the purification.

TABLE 3.1

Purification of HIV Lysate


	Fractionation Step	Protein mg/ml	Volume ml	Total Protein	HLA I ng/ml	HLA II ng/ml	% Recovery
5	HIV Lysate	1.13	10	11.3	1833	692	100%
	Post Lipid Removal	0.96	10.3	9.8	1726	683	86.7
	Post Affinity Chromatography	0.44	19.5	8.58	<10	<10	75.9
10	Post Concentration	1.01	8.1	8.18	<10	<10	72.3

HIV preparations purified as described typically were devoid of contaminants, including HLA class I or class II. SDS-PAGE with Western Blot analysis of purified HIV preparations consistently demonstrated the presence of gp160, gp120, p66/55, gp41, p10, p24, p17 and p7 employing the pooled human IgG anti HIV.

Example 4

Preparation and Characterization of the Biochemical and Conformational Requirements of MDP Microparticle for Eliciting Adjuvant Effects with Purified HIV

A multiple repeat of muramyl dipeptide (MDP) isolated from *Propionibacterium acini*, formed the core structure of the MDP microcarrier complex of this example. The chemical composition of the monomeric subunit is



MDP has well known immunostimulatory properties which have been extensively evaluated in studies designed to determine its effect on increasing immune function. Those skilled in the art are familiar with this effect.

To date, both MDP isolated from natural sources and synthetic MDP have been associated with significant toxicity when administered to mammals. This toxicity has limited the effectiveness of MDP as a carrier.

A method for the isolation of MDP free from toxic components is provided herein. *Propionibacterium acini* was grown to a mid-stationary growth phase and washed to remove contaminants of bacterial culture origin employing techniques well known to those in the art.

Hydrophobic components contained in the cell walls and cytoplasm were sequentially extracted by successive washes in gradual concentrations of ethanol/methanol/water at elevated temperatures. The resulting MDP microparticle was suspended in 10% ethanol and its concentration was measured by relating its absorbance at 540 nm to the absorbance of turbidity standards. The concentration of the MDP microparticle was adjusted to 1 mg/ml for storage and later use.

Analysis of this preparation demonstrated muramyl dipeptide extensively crosslinked with a microparticle size of 0.1 to 0.2 micron. The terminal dipeptide

amino-linked L-alanine-D-isoglutamine was identical to the monomeric structure shown above. It is well known that there can be differences between bacterial strains and these differences can result in differences in peptide composition, such as terminal peptides with five or more amino acids, changes in dipeptide amino acid composition, in particular L-alanine-L-isoglutamine, and sites where O-acylated beta myristate groups have been incorporated. These are not desirable and account for toxicity and poor adjuvant properties of MDP isolated from natural sources. In a preferred embodiment, the MDP microparticles (0.01-0.2 micron; preferably 0.05-0.1) have amino-linked L-alanine-D-isoglutamine dipeptide. Such a microparticle can be isolated from natural sources, as above, or synthesized using well known synthetic procedures.

Example 5

Preparation and Preliminary Evaluation of MDP-Immunogen Conjugate

The adjuvant effect of the MDP microparticle (0.2u) of the preceding example on antibody production was evaluated employing a poorly immunogenic monoclonal human lambda light chain fragment lacking approximately 22 amino acids at the sulfhydryl bridge ($M_r \sim 18,000$) as the immunogen (I). Two conjugates were made, one in which the immunogen was covalently conjugated to MDP through the carboxyl terminal group and one wherein conjugation was through the amino terminal group. MDP-immunogen conjugates were assembled in a stepwise manner and reagent exchange was performed after each step by centrifugation, supernatant removal and replacement with the required reagent to continue the conjugation sequentially through MDP:immunogen

assembly. The molar ratios that are shown with each reaction and the reagent exchange that was performed after each step prevented multiple point attachment of the immunogen which, from preliminary experiments, significantly reduced immune antibody responses.

Synthesis of MDP:NH₂:Immunogen:CO₂H

Protocol for Efficient Two-Step Coupling of HIV Proteins to Muramyl Dipeptide Using EDC

The following procedure, adapted from a procedure described by Grabarek, Z. and Gergely, J., *J. Anal. Biochem.* 185:1311 (1990), allows for sequential coupling of HIV proteins and peptides to MDP without exposing the HIV protein to 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and thus affecting carboxyls on HIV. This procedure calls for quenching the first reaction with a thiol compound. The reaction is carried out in 2-[N-morpholino]ethane sulfonic acid (MES) (pH 4.5-5.0).

MDP (10 mg) lyophilized from water resuspended in MES (0.5 ml) (pH 4.5-5.0) and 0.5ml EDC (0.5mg~2mM) dissolved in MES (pH 4.5-5.0) were combined and reacted for 15 minutes at room temperature. 2-mercaptoethanol (final concentration of 20 mM) was added to quench the EDC and separated by centrifugation. The reaction mixture was washed once with MES and resuspended in 0.5 ml MES (pH 4.5-5.0). The human λ light chain fragment dissolved in MES was added to the activated MDP at a molar ratio of about 2:1. The PH of the reaction was slowly reused over a 15 minute period to 8.5 by the addition of MES (0.5M pH 8.5) and reacted for 2 hours at room temperature. The concentration of the λ light chain fragment added to MDP was calculated from quantitative analysis of MDP terminal CO₂H group and expressed as mole CO₂H per mg MDP. The reaction was

quenched by adding hydroxylamine to a final concentration of 10 mM. This method of quenching hydrolyzed any unreacted MDP activation sites and resulted in regeneration of the original carboxyls.

5 Other means of quenching involve adding 20-50 mM Tris, lysine, glycine, or ethanolamine; however, these primary amine-containing compounds will result in modified carboxyls MDP. When the MDP is used with an HIV synthetic peptide and modification of that peptide

10 is desired, such as to change hydrophobicity or to attach bio-active compounds, the modification can be attained by adding the desired compound prior to the final quench step. This permits the desired compounds to be added sequentially following the initial coupling

15 with HIV peptides. Bioactive peptides also could be added at desired ratios with HIV peptides as a single step when greater control of peptide immunogeneity is desired. Biological response modifiers such as IL2 are well known to those skilled in the art and could be

20 used for this purpose.

Separation was achieved by centrifugation, a wash step, and resuspension in the buffer of choice.

PREPARATION OF MDP-CO₂H-IMMUNOGEN-NH₂

Synthesis of MDP:NH₂CH₂CH₂NH₂:CO₂H:Immunogen:NH₂

25 Protocol for Efficient Three-Step Coupling of Proteins to Muramyl Dipeptide Using EDC

This procedure allows for sequential coupling of a protein or peptides to MDP without exposing the protein to EDC and thus affecting amino groups on the protein.

30 The procedure employs two intermediate steps conducted sequentially. The initial reaction is carried out in MES (pH 4.5-5.0). MDP (10 mg) lyophilized from water

resuspended in 0.5 ml MES pH4.5 and 0.5ml EDC (0.5mg~2mM) dissolved in MES were combined and reacted for 15 minutes at room temperature. Excess EDC was quenched by the addition of 2-mercaptoethanol (final concentration of 20 mM), and the activated MDP was separated by centrifugation, washed two times with MES and resuspended in 0.5 ml MES (pH 4.5). Diaminoethane ($\text{NH}_2\text{CH}_2\text{CH}_2\text{NH}_2$), dissolved in MES (pH4.5) was added to the activated MDP at a molar ratio of about 10:1. The pH was slowly increased over a 15 minute period by the addition of MES 0.5M pH8.5 and reacted for 1 hour at room temperature. MDP: $\text{NH}_2\text{CH}_2\text{CH}_2\text{NH}_2$ was separated by centrifugation, washed two times with MES and resuspended in 0.5 ml MES pH 4.5. The λ light chain fragment was suspended in 0.5 ml MES pH4.5, and 0.5ml EDC (0.5mg~2mM) dissolved in MES was added and reacted for 15 minutes at room temperature. Excess EDC was quenched by the addition of 2-mercaptoethanol (final concentration of 20 mM) and the activated protein was separated from excess reducing agents and inactivated crosslinkers by size chromatography on an appropriate size gel filtration column. The activated protein was added to the activated MDP: $\text{NH}_2\text{CH}_2\text{CH}_2\text{NH}_2$ at a molar ratio of about 5:1 and reacted for 2 hours at room temperature. The concentration of protein added to MDP was calculated from quantitative analysis of MDP terminal CO_2H group and expressed as mole CO_2H per mg MDP. The reaction was quenched by adding hydroxylamine to a final concentration of 10 mM. This method of quenching hydrolyzed any unreacted MDP activation sites and resulted in regeneration of the original carboxyls. If an HIV synthetic peptide is used as the immunogen and modification if that peptide is desired, such as to change hydrophobicity of that peptide or attach bioactive compounds, the modification can be

accomplished as described above. Separation was achieved by centrifugation, a wash step, and resuspension in the buffer of choice.

It should be noted that bioactive compounds may require the intermediate step described above when attachment through the CO₂H group is desired.

Example 6

Comparative Study of MDP Immunogen Conjugate Against Commercial Adjuvants Including Freund's Complete Adjuvant, RIBI®, Titer Max® and Alum

The adjuvant effect of this MDP microparticle (0.1μ) on antibody production was evaluated employing the poorly immunogenic monoclonal human lambda light chain fragment described in the preceding example (Mr - 18,000) as the immunogen (I). Two conjugates were prepared, one in which the immunogen was covalently conjugated to MDP through the carboxyl terminal group and one wherein the conjugation was through the amino terminal group.

Rabbits (n=5 each group) were immunized subcutaneously with approximately 100 micrograms of lambda light chain attached to 500 microgram MDP and emulsified in squalene. Animals were immunized at monthly intervals and test bleeds were obtained prior to immunization and at two week intervals throughout. The antibody responses to MDP:NH₂-I-CO₂H and MDP:NH₂CH₂CH₂NH₂:HO₂C-I-NH₂ were comparable in activity; however, the MDP:NH₂-I-CO₂H-stimulated rabbits produced at least one additional antibody specificity determined by competitive EIA. The antibody responses obtained were compared to those obtained when conventional adjuvants were employed for antibody response, including Freund's complete adjuvant, Ribi®, Titer Max® and Alum (aluminum hydroxide). Both MDP:HO₂C-I-NH₂ and

MDP: NH₂-I-CO₂H were significantly superior to the conventional adjuvants with immunogen in inducing antibody. Immunogen concentration (100 ug/immunization) and immunization schedule were identical in all groups. Table 6.1 shows the antibody titer measured at bi-weekly intervals and titer is expressed as the reciprocal of the dilution producing a positive reaction as described above. Both MDP conjugates were superior to conventional and well known adjuvants.

TABLE 6.1

Week	*MDP:I CO ₂ H	+MDP:I NH ₂	Freund's Complete	Ribi	Titer Max	Alum
T-0	---	---	---	---	---	---
2	---	---	---	---	---	---
4	2	---	---	---	---	---
6	16	4	---	---	---	---
8	256	128	---	---	---	---
10	512	512	4	4	4	---
12	1024	512	16	16	16	---
14	4096	2048	32	32	64	4
16	4096	4096	64	128	256	8
18	8192	4096	256	512	1024	32
20	16384	8192	256	512	2048	32

T-0 = Primary immunization and pre-immunization blood collection.

MDP:I muramyl dipeptide:immunogen micro particle ($\leq 0.2\mu$).

* Peptide was conjugated at amino terminal group to isoglutamine with carboxy terminus exposed. (MDP:I:CO₂H)
+ Peptide was conjugated at carboxy terminus through an intermediate step employing diaminoethylene to modify the carboxyl terminus of MDP. (MDP:I:NH₂)

Example 7

Cytokine Response of Peripheral Blood Mononuclear Cells Induced with MDP:NH₂:I:CO₂H and MDP:NH₂CH₂CH₂NH₂:O₂HC-I-NH₂ Immunogens

5 To further evaluate the mechanisms associated with
the increased antibody response to the MDP
microparticle-immunogen complexes, an in vitro method
which measured cytokine production or peripheral blood
mononuclear cells was employed and compared to known
10 cytokine inducers. Lipopolysaccharide (LPS) and LPS
with phytohemagglutinin (PHA) were employed as known
cytokine inducers. Cytokines were quantitated
employing a well-established assay and expressed as
units/ml. Peripheral blood mononuclear cells were
15 isolated by Ficol Hypaque gradient centrifugation and
adjusted to a concentration of 2×10^6 /ml in tissue
culture media. Cells (100ul) were plated into
microculture wells. MDP:I:CO₂H, MDP:I:NH₂, PHA + LPS,
LPS and media alone were added undiluted or diluted
20 1:10 and 1:25 (10 ul). Cultures were incubated at 37°C
in a 5% CO₂ atmosphere for 48 hours and supernatants
were removed and assayed by standard bioassays and/or
EIA methods.

TABLE 7.1

	IFNR	IL2	TNF	IL6
MDP:I:CO ₂ H	550	510	152	62
MDP:I:NH ₂	520	495	176	73
LPS + PHA	340	320	495	450
LPS	210	150	325	310
MEDIA	0	0	0	0
I:CO ₂ H	496	398	68	25
NH ₂	23	410	72	21
LPS + PHA	205	165	210	152
LPS	175	90	135	140
I:CO ₂ H	125	90	5	10
I:NH ₂	51	85	9	10
LPS + PHA	20	10	15	20
LPS	20	10	15	20

- 15 Both MDP:I:CO₂H and MDP:I:NH₂ stimulated greater Type I cytokine responses than LPS +PHA or LPS alone. Type 1 cytokine responses enhanced immune events while Type 2 cytokine response is indicated by elevated IFN gamma and IL2 and lower levels of TNF and IL6.

20 Example 8

Characterization of the Antibody Response in Goats to HIV Proteins Untreated and Treated to Remove Carbohydrates Moieties and Comparison of the Adjuvant Properties of MDP Microparticles with Conventional Adjuvants

25 Example 8.1

HIV_{1MN}, HIV_{1BAL} and HIV_{2NZ} viral lysates were purchased from Advanced Biotechnologies Inc., Columbia, MD. and one-half of each preparation was treated enzymatically to remove carbohydrate and all preparations (with and without carbohydrate) were purified as above. An aliquot of each was conjugated to MDP through the amino terminal residue in accordance with the procedures set forth in Example 5, and

individually suspended in squalene. For comparison, these HIV proteins also were emulsified in Freund's complete adjuvant without conjugation to MDP.

- 5 Group 1 - HIV1_{MN} : HIV1_{BAL}, 1:1, without carbohydrate removal;
- Group 2 - HIV1_{MN} : HIV1_{BAL}, 1:1, with carbohydrate removal;
- Group 3 - HIV2_{NZ} without carbohydrate removal;
- Group 4 - HIV2_{NZ} with carbohydrate removal
- 10 Group 5 - HIV1_{MN} : HIV1_{BAL} : HIV2_{NZ}, 1:1:1, without carbohydrate removal;
- Group 6 - HIV1_{MN} : HIV1_{BAL} : HIV2_{NZ}, 1:1:1, with carbohydrate removal;
- Group 7 - HIV1_{MN} : HIV1_{BAL}, HIV2_{NZ}, 1:1:1, without carbohydrate removal and emulsified in Freund's complete adjuvant without conjugation to MDP.
- 15 Group 8 - HIV1_{MN} : HIV1_{BAL} : HIV2_{NZ}, 1:1:1, with carbohydrate removal and emulsified in Freund's complete adjuvant with conjugation to MDP.
- 20 Goats were stratified into immunization groups 1-8 (n=3 each) and respectively immunized at the intervals shown in Table 8.1 with 100 ug HIV/immunization. Blood samples were obtained prior to immunization and at biweekly intervals. Antibody reactivity was
- 25 quantitated by EIA using the FDA approved commercially available test kit from Abbott Laboratories. Results were expressed as the reciprocal of the antisera dilution that produce an absorbance value >1.0.

TABLE 8.1
Analysis of Anti HIV Antibody Response to HIV Proteins

Week #	Group 1 Anti HIV1	Group 2 Anti HIV1 ¹	Group 3 Anti HIV2	Group 4 Anti HIV2 ²	Group 5 Anti HIV1&2	Group 6 Anti HIV1&2 ¹	Group 7 Anti HIV1&2	Group 8 Anti HIV1&2
T-O*	0	0	0	0	0	0	0	0
2	0	0	0	0	0	0	0	0
4*	8	8	8	4	8	8	0	0
6	64	64	32	16	64	128	2	0
8*	64	128	32	32	64	128	4	2
10	512	512	64	128	256	512	16	8
12*	512	1024	128	256	512	1024	16	16
14	2048	2048	512	512	1024	2048	32	32
16*	4096	4096	256	512	4096	4096	64	32
18	4096	8192	512	1024	8192	8192	128	54
20	8192	16384	1024	1024	16384	16384	128	64

T-O = Primary immunization and pre-immunization blood collection

1 - Carbohydrates removed

* - Immunization & Booster

The antibody responses were measured at bi-weekly intervals throughout immunization. There was no significant difference in antibody reactivity, measured by EIA, between individual animal groups (Groups 1&2, 3&4, 5&6) with MDP. Carbohydrate removal had no effect on production of antibody to the desired anti-HIV proteins.

Example 8.2

Antisera obtained as described in Example 8.1 were evaluated for hemagglutinating antibodies. As can be seen from Table 8.2, carbohydrate removal from the HIV proteins obliterated the hemagglutination response.

TABLE 8.2
Analysis of Anti HIV Antibody Response to Red Blood Cells

Week #	Group 1 Anti HIV1	Group 2 Anti HIV1 ¹	Group 3 Anti HIV2	Group 4 Anti HIV2 ²	Group 5 Anti HIV1&2	Group 6 Anti HIV1&2 ¹	Group 7 Anti HIV1&2	Group 8 Anti HIV1&2 ¹
T-0*	--	--	--	--	--	--	--	--
2	--	--	--	--	--	--	--	--
4*	--	--	--	--	--	--	--	--
6	2	--	2	--	4	--	4	--
8*	4	--	4	--	4	--	8	--
10	16	--	8	--	8	--	16	--
12*	32	--	8	--	32	--	16	--
14	64	--	64	--	128	--	64	--
16*	64	--	64	--	64	--	128	--
18	128	--	128	--	128	--	256	--
20	256	--	256	--	128	--	256	--

T-0 = Primary immunization and pre-immunization blood collection

1 - Carbohydrates removed

* - Immunization & Booster

HIV preparations treated to remove carbohydrate groups failed to produce antibody reactivities able to agglutinate red blood cells (Table 8.2A). Goats immunized with MDP-HIV conjugates without carbohydrate depletion and a goat immunized with purified HIV without carbohydrate depletion emulsified in Freund's complete adjuvant produced red cell agglutinins. There was no detectable difference in the titer of red cell agglutinins in antisera from goats immunized with MDP-HIV conjugates or HIV emulsified in Freund's complete adjuvant. The red cell agglutinins described herein were essentially identical to those described in the preliminary studies of Example 2. These agglutinins were cytotoxic (Table 8.2A). However, there was no detectable antibody reactivity to HLA class I or class II and absorption with red blood cells completely removed both the hemagglutinating and the cytotoxic antibody reactivity.

TABLE 8.2A
Sequential Analysis of Anti HIV Antibodies for Lymphocytotoxicity

Week #	Group 1 Anti HIV1	Group 2 Anti HIV1 ¹	Group 3 Anti HIV2	Group 4 Anti HIV2 ²	Group 5 Anti HIV1&2	Group 6 Anti HIV1&2 ¹	Group 7 Anti HIV1&2	Group 8 Anti HIV1&2 ¹
T-O*	±	±	±	±	±	±	±	--
2	±	±	±	±	±	±	±	--
4*	+4	±	+2	±	+4	±	±	--
6	+8	±	+2	±	+8	±	+2	--
8*	+8	±	+4	±	+16	±	+4	--
10	+64	±	+32	±	+32	±	+4	--
12*	+256	±	+256	±	+128	±	+16	--
14	+256	±	+512	±	+256	±	+32	--
16*	+512	±	+512	±	+512	±	+64	--
18	+512	±	+1024	±	+512	±	+128	--
20	+512	±	+1024	±	+1024	±	+128	--

T-O = Primary immunization and pre-immunization blood collection

1 - Carbohydrates removed

* - Immunization & Booster

To evaluate the possibility of mimicry between HIV and RBC carbohydrate groups, additional antisera were produced by immunizing a goat with an immunogen composed of purified and pooled cell membranes isolated from human red blood cells. Western Blot analysis employing this antisera demonstrated reactivity with a red blood cell glycoprotein (~Mr35,000) and reacted with HIV gp41 and gp120. However, HIV gp41 and gp120 treated to remove carbohydrate groups were unreactive. These data were consistent with phylogenetic mimicry between carbohydrate epitope on HIV and red blood cell glycoproteins.

Western Blot analysis demonstrated strong reactivity to most HIV proteins, including gp160, gp120, gp41, p66/55, p10, p24, p17 and p7. There was no apparent difference in the reactivity or specificity of these antibodies to the HIV epitopes disclosed herein. These antibodies reacted to all HIV isolates tested, including those which have been shown to have resistance to reverse transcriptase and protease inhibitors.

Example 8.3

Neutralization of HIV Infectivity by Antibodies produced to Carbohydrate-Depleted HIV

This example describes and characterizes the neutralization of HIV infectivity using the antibodies produced to carbohydrate depleted HIV disclosed above. The results indicate that these antibodies contain high levels of neutralizing activity and protect CEM cells from infection in a dose dependent manner.

Neutralization Assay:

A sensitive neutralization assay was employed to quantitate the effect of goat anti HIV on HIV infectivity. The CEM CD4⁺ cell line, which is highly

susceptible to HIV infection, was chosen as the target cell to determine the effect of this antibody on HIV infectivity. The antibody and dilutions were made as required in RPMI medium containing 10% fetal calf serum. A suspension of HIV_{1SF2} was harvested from about four-day cultures of CEM in log growth phase, filtered through 0.2 or 0.45 micron filters, aliquoted, and frozen at -70° C. One aliquot was thawed, titrated to determine the TCID₅₀, and subsequent assays were performed with freshly thawed aliquots, diluted 1:500 in culture medium to a concentration of approximately ten times the amount required to infect 50% of CEM cells in culture (10 TCID₅₀). The virus suspension was mixed with an equal volume (250 ul) of five-fold dilutions of antibody from 1:5 to 1:9,765,625. The virus/antibody mixture was incubated for 60 minutes at 37° C. and duplicate samples of 200 ul used to inoculate wells containing 1.0 ml of approximately 2x10⁵ CEM cells per well. The cultures were incubated at 37° C. in a humidified, 5% CO₂ atmosphere for 14 days. The cells were harvested, pelleted, and lysed with 1% Triton X-100 in PBS for about 10 minutes. The amount of virus (or viral antigen) present in lysed cells was quantitated using a commercially available p24 assay. The titer of neutralizing activity was determined as the reciprocal of the dilution of antibody which inhibited p24 antigen production by greater than 50% of virus control cultures incubated without antibody, or with goat pre-immune IgG prepared in a similar manner. Two hundred microliters of the lysed cellular suspension were assayed.

TABLE 8.3A
Analysis of Anti HIV Antibody Neutralization Activity

Week #	Group 1 Anti HIV1	Group 2 Anti HIV1 ¹	Group 3 Anti HIV2	Group 4 Anti HIV2 ²	Group 5 Anti HIV1&2	Group 6 Anti HIV1&2 ¹	Group 7 Anti HIV1&2	Group 8 Anti HIV1&2
T-O*	--	--	--	--	--	--	--	--
2	--	--	--	--	--	--	--	--
4*	--	--	--	--	--	4	--	--
6	32	16	--	--	16	16	--	--
8*	256	32	4	--	64	128	2	--
10	1024	128	4	4	512	256	8	--
12*	1024	512	16	8	2048	1024	32	--
14	5096	1024	256	32	5096	2048	64	--
16*	10192	2048	512	64	10192	2048	128	--
18	20384	2048	1024	128	20384	5096	128	--
20**	20384/204	5096/5096	2048/256	256/256	40766/101	10192/101	256/12	--

T-O = Primary immunization and pre-immunization blood collection

1 - Carbohydrates removed

* - Immunization & Booster

** = anti-Hiv preparations obtained from the week 20 bleeds were absorbed with human red blood cells and both unabsorbed and absorbed samples were tested under identical conditions. Results are expressed as (unabsorbed/absorbed) neutralization titer.

The anti HIV preparations with the greatest neutralizing activity were produced to HIV-MDP conjugates that were not treated to remove carbohydrate determinants (Table 8.3A). Red blood cell absorption of antibodies to carbohydrate-depleted HIV conjugates had no effect. However, RBC absorption of antibodies to carbohydrate-intact HIV conjugates resulted in a significant reduction in neutralizing reactivity, confirming the presence of phylogenetically present carbohydrate moieties shared between HIV and humans (bottom row, Table 8.3A). All anti-HIV antibody preparations produced to HIV-MDP conjugates were statistically greater than anti-HIV produced using Freund's complete adjuvant. Due to the predicted genetic variability characteristic of HIV, anti-HIV from the 20 week preparations were tested for neutralizing activity using HIV_{MN} and four HIV wild isolates, including one characterized as a multi-drug resistant strain under conditions identical to those described above. Anti-HIV from the 20 week antibody preparations produced to HIV conjugates devoid of carbohydrate neutralized all strains (Table 8.3B).

Those skilled in the art will recognize that the neutralizing activity produced to HLA-depleted, carbohydrate-depleted HIV proteins is considerably higher than the neutralizing activity typically observed in human anti-HIV sera.

TABLE 8.3B

Analysis of Anti HIV Antibody
Neutralization Activity
Against Multiple Strains

5	HIV Strain / Isolate	Anti HIV1 ¹	Anti HIV2 ¹	Anti HIV1&2 ¹	Pre Immune IgG
	HIVSF	10192	512	20384	0
	HIVMN	5096	256	10192	0
	Wild#1	10192	512	20384	0
10	Wild#2	2048	256	5096	0
	Wild#3	2048	128	5096	0

¹=carbohydrates removed

Example 8.4

15 Effect of Anti HIV on HIV Infected CD4 Lymphocytes in
an Antibody Dependent Complement Mediated Cytotoxicity

Antibodies against carbohydrate-depleted and
carbohydrate-intact HIV conjugates were evaluated for
complement mediated cytotoxicity reactivity to normal
20 peripheral blood mononuclear cells enriched for CD4
lymphocytes with and without infection with HIV.
Normal peripheral mononuclear cells were isolated,
subjected to Ficoll Hypaque gradient centrifugation and
enriched for CD4⁺ lymphocytes. CD4⁺ lymphocytes were
25 stimulated with PHA and infected with HIV_{MN} for 7 days
in micro culture. Supernatants were removed and
replaced with anti HIV produced to HIV preparations
following sugar group removal and shown to have no
cytotoxic effects on normal cells. As can be seen in
30 Table 8.4, anti HIV lysed infected CD4 lymphocytes in a
dose dependent fashion.

TABLE 8.4
Analysis of Anti HIV Antibody Mediated Cytotoxicity of Infected CD4 Lymphocytes

Week #	Group 1 Anti HIV1	Group 2 Anti HIV1 ¹	Group 3 Anti HIV2	Group 4 Anti HIV2 ²	Group 5 Anti HIV1&2	Group 6 Anti HIV1&2 ¹	Group 7 Anti HIV1&2	Group 8 Anti HIV1&2 ¹
T-O*	±	±	±	±	±	±	±	--
2	±	±	±	±	±	±	±	--
4*	4	4	2	±	4	4	±	--
6	8	16	2	±	32	32	±	--
8*	32	32	4	4	256	256	2	--
10	128	64	32	32	512	512	8	--
12*	256	128	256	64	1024	1024	16	--
14	1024	512	512	256	2048	2048	16	2
16*	2048	1024	512	256	4096	4096	32	4
18	4096	2048	1024	512	8192	8192	64	8
20	8192	4096	1024	512	8192	8192	256	8

T-O = Primary immunization and pre-immunization blood collection

1 - Carbohydrates removed

* - Immunization & Booster

Example 8.5Synthesis of Peptides Corresponding
to the Amino Acid Sequence of HIV Proteins

Synthetic peptides were constructed as twelve-mer
5 peptides which mimic the amino acid sequence of HIV_{1SF2}.
Amino acid sequences for gp 120, gp 41, Vif, gag p 17,
gag p 24, nef, Rev, Integrase, Protease, Tat:HxB2 and
Reverse Transcriptase and Reverse Transcriptase with
overlaps by six amino acid residues were synthesized by
10 and purchased from Purification Systems, Inc.
employing solid phase technology.

Butyloxycarbonyl-S-4-methylbenzyl-L-cystine
coupled to polystyrene using dicyclohexylcarbodiimide
with a catalytic amount of 4-N,N-dimethylaminopyridine
15 was used as the solid-phase support for the synthesis.
The amino groups were protected with
tert-butyloxycarbonyl (t-BOC) and the side chain
protecting groups were as follows: benzyl ether for
the hydroxyl of serine, dichlorobenzyl ether for the
20 phenolic hydroxyl of tyrosine, and the beta
benzyl-esters were used for the carboxyl groups on
glutamic acid and aspartic acid, respectively.
Trifluoroacetic acid (40% in CH₂Cl₂) was used to remove
t-BOC and the resulting salt was neutralized with
25 N-diisopropylethylamine (10% in CH₂Cl₂).
Diisopropylcarbodiimide was used to couple the t-BOC
amino acids. The protecting groups were removed and
the peptide was cleaved from the resin at 0° degrees C.
with anhydrous hydrogen fluoride containing 10%
30 anisole and 1% ethanedithiol as scavengers. The
hydrogen fluoride reagent was removed under vacuum at
0° C and the peptide then was precipitated and washed
with anhydrous ether. After extraction of the peptide
from the resin with trifluoroacetic acid, the solvent

was evaporated to 15° C. and the peptide was again precipitated with ether. The ether was decanted after centrifugation and the pellet was dissolved in 5% acetic acid with 6 M guanidine HCl. This solution was desalted on a BioGel P2 column equilibrated in 5% acetic acid and the peptide containing fractions were pooled and lyophilized. A cysteine residue was added to the carboxyl terminus of the peptide as needed to provide a functional SH group for the coupling of the peptide to carrier proteins or to a solid support for EIA procedures or to MDP (Example 5). When multiple repeats of the peptide were desired, synthesis was conducted by first attaching a cysteine residue to the resin support. Carbon spacers of various lengths were added; the choice of spacer length varied and was dependent on the application, peptide charge and length and steric influences predicted from preliminary data resulting from peptide attachments to supports. A six carbon spacer such as 6-aminohexanoic acid was first attached with lysine- (lysine)₂-(lysine)₄ additions as described above with diaminoethane in Example 5 but altering the sequence of protective group blocking. Amino groups were protected and then deprotected to permit two lysine residues to attach to the deprotected amino terminus, deprotection followed by lysine addition built a branched chain structure for peptide synthesis. Peptides with specific biological function or with sequences that are susceptible to enzymatic degradation were modified by the addition of D-amino acids. One particularly useful addition is the addition of L-alanine-D-isoglutamine with the peptide of interest synthesized off of the NH₂ terminus of D-Isoglutamine. In another arrangement, the peptide was synthesized with L-Lysine-L-Lysine-peptide-D-isoglutamine. The carboxy terminal lysine groups are

highly susceptible to enzyme degradation by many enzymes in the micro environment while D-isoglutamine both results in an increase in half life of the peptide and provides a hydrophobic site to assemble peptides that require amphipathic properties to elicit a function such as receptor binding and immune induction through MHC associated events. A tyrosine residue was added to the amino terminus for radioactive labeling with ¹²⁵Iodine to determine peptide-to-carrier protein coupling efficiency and to identify the peptide during purification. ¹²⁵I also provided a tracer to follow the half life of the peptide in biological systems and evaluate receptor binding when peptide function was not affected by tyrosine addition.

Example 8.6

The use of synthetic peptides which mimic peptide sequences of HIV and other retroviruses, for the identification of viral epitopes

Within this invention, synthetic peptide sequences which mimic highly conserved sequences found in HIV and other retroviruses are disclosed and their functional significance as immunological targets in treating viral infections are identified. These peptides have further application in the diagnosis and management of HIV infection resulting from HIV microvariants with sequences that contribute to the pathogenesis of HIV through nonspecific down regulation of immune reactions, induction of autoimmunity, and through toxic effects leading to HIV-associated peripheral neuropathy. Each of these events, when presented in a patient, contribute to the pathogenesis of HIV and decline in the quality of life. Synthetic peptides employed to identify and quantitate those HIV-peptide

regions which initiate those events, have utility in identifying risk factors for autoimmunity and peripheral neuropathy. The synthetic peptides provide further utility in a novel assay procedure to monitor disease progression and changes in progression as a result of treatment.

In one step of this invention, an enzyme immunoassay (EIA) was configured for the identification of goat antibody specificities on HIV not recognized by human anti-HIV. Purified preparations of HIV1 gp120 and gp41 proteins were coated on wells of polyvinyl microtitre plates at 5 ug/ml in phosphate buffered saline (PBS< pH 7.8) by incubation for twenty hours at 37°C. The wells were washed with PBS containing 0.1% Tween 20 (PBS/Tween) and the unoccupied sites of each well were saturated with 5% bovine serum albumin by incubation for 1 hour at 37°C. The plates were used immediately or stored at 4°C. Human IgG anti-HIV (100 ul) (Example 1) was added to each well, incubated for 25 hours at 4°C, and the wells were washed with PBS/Tween. Goat anti-HIV previously produced and labeled with HRP by standard procedures was added to the wells at a dilution required to yield an absorbance of 1.0 in the conditions of the assay (1:10000 titre) and incubated for 24 hours at 4°C. The wells were washed and substrate added to determine amount of binding of the goat IgG. The percent inhibition of binding induced by blocking HIV proteins with human anti-HIV was calculated using the formula.

$$\frac{(\text{OD not blocked} - \text{OD blocked})}{\text{OD not blocked}} \times 100 - \text{OD blocked negative control}$$

Minimal blocking of goat anti-HIV-HRP conjugate by human anti-HIV was indicative of binding of goat anti-HIV different from human anti-HIV.

In another step, an EIA was configured to identify epitopes on HIV proteins that were antigenic with goat antibodies but not with human antibodies. Purified preparations of HIV1 gp120 and gp41 proteins were

5 coated on polystyrene beads at 5 ug/ml in PBS by incubation for twenty hours at 37°C. Beads were washed with PBS containing 0.1% Tween 20 (PBS/Tween) and the unoccupied sites on each bead were saturated with 5% bovine serum albumin by incubation for 1 hour at 37°C.

10 Beads were used immediately or stored at 4°C. Human IgG anti-HIV (100 ul) (Example 1) was added to each bead, incubated for 24 hours at 4°C. Human IgG anti-HIV (100 ul) (Example 1) was added to each bead, incubated for 24 hours at 4°C and the beads were washed

15 with PBS/Tween. Synthetic peptides were dissolved in PBS containing bovine serum albumin (5mg/ml) and Tween 20 (0.1%) at a concentration of .1 mg/ml. The peptides (25 ul) were added to goat anti-HIV IgG-HRP conjugate solution (100 ul) and incubated for 24 hours at 4°C.

20 The mixture then was added to two sets of beads coated with HIV. One set was blocked with human anti-HIV that was added to two sets of beads coated with HIV. One set was blocked with human anti-HIV that was added at the same time as the peptides were added to the goat

25 anti-HIV-HRP conjugate. The beads with reactants were incubated for 24 hours at 4°C. Following incubation, the beads were washed and peroxidase activity was measured as described above. Activity was plotted against peptide position within the HIV proteins.

30 These plots showed areas of the HIV proteins targeted by goat HIV immune IgG that was not recognized by human antibody. When inhibition of binding was observed with a specific synthetic peptide, additional peptides were synthesized to overlap the original peptide by peptides

35 of additional lengths. The lack of inhibition by the

synthetic peptides was considered to represent lack of immunologic targeting by the goat immune system. Employing this procedure, linear peptide epitopes were selected for study.

5 In another preferred procedure of this invention, an EIA was configured to utilize peptide-peroxidase conjugates, produced as disclosed below, to identify antibody reactive epitopes on HIV proteins recognized by the goat but not by the human immune system. Peptides
10 mimicking HIV sequences were covalently attached to HRP to produce an enzyme labeled peptide library for use in mapping antibody specificity. Specifically, HRP was dispensed into a reaction tube at a calculated molar ratio of 1 part HRP:10 parts peptide. Each peptide to
15 be coupled was individually dispensed into microtubes at a concentration of 0.1 - 1 umole/ml at volumes of 0.1 - 1 ml, each of which varied dependent upon quantity of conjugate desired and molecular weight to peptide. HRP at a concentration of 1-10 umole/ml was
20 dissolved in 0.1 M carbonate/bicarbonate buffer (pH 9.8) at 4°C and sodium periodate was added to achieve a final concentration of 0.02 M. The mixture was immediately dispensed into the microtubes containing the peptides mixed and reacted for 30 minutes.
25 Ethylene glycol (0.02 M) was added to quench remaining sodium periodate. The intermediate Schiff's base formed between the amino terminus of the peptide and the aldehyde formed by oxidation of the HRP carbohydrate moieties was reduced by the addition of
30 sodium borohydride (0.2 M) in water. Chromatography of each peptide-proxidase conjugate in Sephadex G25 was used to remove reactants and excess peptide.

 In this preferred assay, the antibody was used to bridge epitopes identified on the HIV proteins prepared
35 from HIV virus lysates and synthetic HIV peptides

covalently attached to HRP since antibody reactive with HIV epitopes retained an antigen-binding site which could react with synthetic peptide epitopes attached to peroxidase. Beads were coated with HIV proteins as described above. Coated beads were reacted with goat anti-HIV IgG for 24 hours, the beads were washed and reacted with substrate to determine peroxidase activity and, therefore, peptide binding. With this procedure, only exact epitopes contained within the synthetic peptide were recognized. In this assay, the complete repertoire of goat reactivities was identified. Human anti-HIV and goat anti-HIV reactivities were compared and peptides that reacted only with goat anti-HIV were selected as candidate epitope targets. These data were not considered to be all inclusive of differences between human and goat reactivity to HIV proteins since differences between reactivities and shifts between the amino acid peptide sequence homologies on the HIV protein could result in missing epitope reactivity secondary to the selection of the synthetic peptide.

Example 9

Antibody Efficacy as a Therapeutic Agent

A study was conducted with a group of immunochemically designed antibodies to determine the efficacy of the antibodies as a therapeutic agent for the treatment of HIV/AIDS. Specifically, a mixture of lysates of HIV isolates HIV1_{MN}, HIV1_{BAL} and HIV2_{NZ}, was treated as in Example 3 to remove low molecular weight contaminants and HLA class I and class II antigens and to deglycosylate the HIV proteins. The protein mixture was assayed and found to comprise peptides which mimic the following regions of HIV1_{sf2} proteins:

gpl20: an epitope region extending from amino acid residue 4-27 and a second epitope region extending from amino acid residue 54-76;

5 gp41: an epitope region extending from amino acid residue 502-531;

reverse transcriptase heterodimer p66/55: an epitope region extending from amino acid residue 254-295;

10 protease p10: an epitope region extending from amino acid region 69-94;

Gag gene protein p24: an epitope region extending from amino acid region 166-181;

15 Gag gene protein p17: an epitope region extending from amino acid region 2-23 and a second epitope region extending from amino acid region 89-122; and

Gage gene protein p7: an epitope region extending from amino acid region 390-41 and 438-443.

20 These amino acid sequences fail to elicit an immune response in humans when contacted through infection or naturally through the environment but do elicit an immune response in other mammalian species.

The purified and treated proteins were enriched and further purified using preparative SDS-PAGE electrophoresis and when desired, by immunoaffinity chromatography employing commercially available (ICN 25 Costa Mesa, CA and Advanced Biotechnologies, Columbia, MD) monoclonal antibodies to gp120, gp41, pp 66/55, p24, p17 and p10 each individually coupled to Sepharose CL4B using procedures known in the art. Following 30 purification, each purified HIV protein peptide of interest was individually conjugated to the MDP microparticle as described in Example 4. HIV-MDP microparticle conjugates were formulated as a cocktail containing equal molar concentrations of each HIV 35 protein/peptide at a final concentration of

approximately 1mg protein/ml in physiological saline. The HIV-MDP cocktail (0.5 ml) was emulsified in squalene (1.5 ml containing 0.05% Tween 80) and injected subcutaneously into 60 goats at 4 to 6
5 injection sites per goat. Booster immunizations were given at monthly intervals to achieve the desired antibody responses. Monthly serum samples were obtained from each goat preceding the monthly booster and tested by Western Blot analysis, HIV neutralization
10 and enzyme immunoassay disclosed in Example 8.6. Once the desired antibody response was achieved, goats were plasmapheresed from the jugular vein employing a Baxter A 201-A401 Autophoresis machine. The goat red blood cells were returned in physiological saline. The
15 volume of plasma collected from each animal at each plasmapheresis was 350 ml \pm 5.0 ml.

The Caprine immune plasma was fractionated with octanoic acid, after adjustment of the pH to 4.8 with hydrochloric acid. The mixture was centrifuged,
20 filtered and passed through an activated charcoal filter to remove agglomerates and reduce the octanoic acid level to below 0.05%. The immunoglobulin (IgG) containing fraction was further purified by passage through a series of columns:

- 25 1. Sephadex G25 with 20mM phosphate buffer
2. Ion exchange with Whatman DE53 equilibrated in phosphate buffer
3. Sephadex G25 equilibrated in 0.9% saline

The final column filtrate was sterile filtered and then
30 either concentrated or diluted to give a final concentration of 10 mg IgG/ml with the desired biological activity. SDS-PAGE and Western Blot analysis demonstrated reactivity of caprine IgG immunoglobulins at a 1:100 dilution with the seven
35 distinct viral proteins as gp120, gp41, p51/66, p24,

p17, p7 and p10. Analysis for HIV neutralization demonstrated broad neutralization of HIV1 laboratory and wild strains as disclosed in Example 8.3. Analysis by the enzyme linked immunoassay disclosed in Example 8.3 demonstrated positive reactions to the desired nine epitopes at sample dilutions of 1:1000 or greater. Production lots meeting these criteria were given the trade name of HRG214 as disclosed and consisted of sterile, pyrogen free caprine IgG at a concentration of 10mg/ml suspended in 0.9% sodium chloride without excipients. Each production lot is compared to the reference lot as disclosed herein to determine equivalence of HRG214 activity. Potency is expressed as mg equivalent/ml.

Males and non pregnant females over the age of 18 were selected based on their having a serodiagnosis of HIV infection documented by Western Blot, with AIDS defining criteria, clinically symptomatic, and with a CD4 T lymphocyte count < 300 cells/ul within 30 days prior to study entry. Clinical and laboratory parameters were used to evaluate efficacy. Clinical parameters included changes in opportunistic infections, changes in body weight, changes in gastrointestinal function, including stool consistency and frequency, changes in energy level, changes in appetite, physical strength and endurance, and an overall change in the quality of life. Laboratory parameters included changes in CD4 and CD8 lymphocyte numbers, selected hematology, blood chemistry and urinalysis, and, when available, changes in viral loads by measuring viral RNA by PCR.

The study results showed that with the use of the immunochemically designed antibodies patients improved clinically, with decreases in opportunistic infections, increases in body weight, changes in gastrointestinal

function, including less severe diarrhea, increases in energy level, increases in appetite, improvements in physical strength and endurance, and an overall improvement in the quality of life. Laboratory parameters showed improvements, with increases in CD4 and CD8 lymphocyte numbers, improvements in hematology, blood chemistry, and urinalysis numbers, as well as decreases in viral loads by measuring viral RNA by PCR and decreases in infectivity when measured by TCID.

10 The detailed laboratory results of the study are set forth in the attached Tables 9.1 - 9.13:

Example 9.1

Clinical Evaluation of the Toxicity and Efficacy of HRG214 in Treating HIV-Infected Patients

15 Thirty-five HIV infected patients were treated with HRG214. HRG214 was evaluated for efficacy in reducing HIV viral burden and ameliorating disease progression and symptoms. Patients were stratified by CD4 number/mm³ (<200 and ≥200) and therapeutic regimen:

20 Group 1: HRG214, CD4<200, n=11;
Group 2: HRG214 and monthly retreatment, CD4<200, n=6;
Group 3: HRG214 and retreatment at progression, CD4<200, n=5;

25 Group 4: HRG214, CD4>200, n=7;
Group 5: HRG214 and retreatment at progression (patients receiving chemotherapy for malignancy), CD4<200, n=6;

30 Group 6: Placebo control, CD4>500, n=19;
Group 7: Placebo control, CD4>200-500, n=3.

Patients in treatment groups received 21-28 daily infusions of HRG214 at 1-1.5mg/kg body weight. Patients with CD4 <200 were either retreated x3 days

monthly (n=6) or retreated with evidence of HIV progression (n=11). Adverse reactions were limited to minor fever of $< 2^{\circ}\text{F}$, chills, headache, and muscle ache. Clinical chemistry and hematology measurements during and after treatment remained unchanged or improved in all patients over a 90 day period. Twenty-eight patients were evaluated for change in nutritional status. Twenty-four gained 2-22 lbs. body weight with a mean increase of 4.4 lbs. ($p=0.0014$). Four of the six patients receiving systemic chemotherapy for malignancy remained stable (n=2) or lost weight (2 and 6 lbs respectively). Weight increases correlated directly with increases in serum total protein and albumin measurements. Quantitative HIV-RNA decreased in all treatment groups.

Group #: Days followed Total=n, Survivor=S		CD4# Pre/Post	CD8# Pre/Post	HIV RNA % Change
5	Group 1 ^{HRG214} : Day 150, n=11, S=4	153/156	601/699	- 18%
	Group 2 ^{HRG214} : Day 345, n= 6, S=6	44/168	477/1143	- 94%
	Group 3 ^{HRG214+} : Day 469, n= 5, S=3	25/67	705/856	- 67%
10	Group 4 ^{HRG214} : Day 405, n= 7, S=7	315/487	970/1164	- 94%
	Group 5 ^{HRG214+} : Day 469, n= 6, S=2 Chemo	43/41	476/592	- 54%
15	Group 6 ^{control} : Day 469, n=19	909/628	NA	NA
	Group 7 ^{control} : Day 469, n=3	315/177	NA	NA

The rate of CD4/mm³ loss with time in all treatment groups was reduced (p<0.01) compared to control groups 6 and 7. A sustained CD4 increase was observed in groups 2, 3 and 4. Infectivity measurements by microculture (TCID) demonstrated a 2 log reduction in infectivity by treatment day 7-14 (p<0.001) which was not obvious from quantitative HIV-RNA measurements.

Clinical changes included increases in appetite and stamina with marked improvements in chronic fatigue syndrome, diarrhea, malabsorption, candidiasis, CMV (retinitis excluded), Herpes simplex and zoster, cutaneous Molluscum contagiosum, oral hairy leukoplakia, wasting syndrome, bacterial folliculitis and pneumonitis and HIV related peripheral neuropathy were observed.

HRG214 offers a new drug to assist in the management of HIV infection.

Data for patient groups 2-5 are presented in more detail below:

Patient Group 2

Patient n = 6

5 **Primary Objective:** Evaluate safety and efficacy of HRG214 treatment of HIV infection at a daily dose of 1.5 mg/kg/day for 28 days and monthly retreatment x3. Clinical follow-up will continue for 3 years. Patients will have retreat options with recurrence.

10 **End Points:** Normalization of clinical and laboratory parameters including improvement in opportunistic infections, incidence of infections, wasting syndrome, peripheral neuropathy and improvement in abnormal blood chemistry and hematology, CD4 and CD8
15 and reductions in HIV-RNA quantitated by PCR.

Safety variables include: Blood chemistry and hematology and clinical parameters.

Efficacy variable include: HIV-RNA Quantitative by PCR, CD4 and CD8 counts.

20 Follow up period = 3 years

Follow-up period to date = >345 days

Study Demographics: Patient n=6; Start Date - 10/23/95; As of day 390, Survivors=6; Deaths=0; Lost to follow up=0.

25 **Patient Demographics:** HIV positive, AIDS defining criteria with CD4 number <50/mm³.

Treatment Drug(s): HRG-214 - 1.5mg/kg/day with monthly retreatments.

Table 9.2
Patient Group 2

HIV-RNA QUANTITATIVE BY PCR					
TEST	DAY 1	DAY 21-28	DAY 60-90	DAY 120-150	DAY 330-390
Mean	4918.3	2092.5	1338	731.8	696.6
Std error	2422.6	1222	927.2	433.1	331.2
Maximum	10649	4880	3993	1825	1164
Minimum	494	23	19	17	15
Median	4265	1733.5	670	542.5	466

Table 9.3
Patient Group 2

QUANTITATIVE CD4/mm ³					
TEST	DAY 1	DAY 21-28	DAY 60-90	DAY 120-150	DAY 330-390
Mean	44	52.8	52.8	109.3	167.8
Std error	14.2	19.1	16.8	33.2	41.7
Maximum	72	96	82	154	189
Minimum	5	4	5	11	23
Median	49.5	55.5	62	136	139

Table 9.4
Patient Group 2

QUANTITATIVE CD8/mm ³					
TEST	DAY 1	DAY 21-28	DAY 60-90	DAY 120-150	DAY 330-390
Mean	477.5	437	603.3	911.8	1143
Std error	157.1	171.8	173.6	228.9	286.7
Maximum	869	883	804	1376	1752
Minimum	145	68	84	319	576
Median	448	398.5	762.5	976	1293

Patient Group 3**Patient n = 5**

Primary Objective: Evaluate safety and efficacy of HRG214 treatment of HIV infection at a daily dose of 1.5 mg/kg/day for 28 days. Clinical follow-up will continue for 3 years. Patients will have retreat options with recurrence.

End Points: Normalization of clinical and laboratory parameters including improvement in opportunistic infections, incidence of infections, wasting syndrome, peripheral neuropathy and improvement in abnormal blood chemistry and hematology, CD4 and CD8 and reductions in HIV-RNA quantitated by PCR.

Safety variables include: Blood chemistry and hematology and clinical parameters.

Efficacy variable include: HIV-RNA Quantitative by PCR, CD4 and CD8 counts.

Follow up period = 3 year

Follow-up period to date = >469 days

Start date of 6/13/95; as of day 380, Survivors = 3; Deaths = 2; Lost to follow up = 0

Patient population: HIV positive patients with AIDS defining criteria. Five (5) of the five (5) patients

had CD4 <50/mm³ blood. HIV-RNA quantitated by PCR demonstrated statistically significant reductions following treatment; day 7 (P = 0.0179) and days 21-28 (P=0.043). HIV RNA measurements on days 60-90 and 120-150 demonstrated reduced but increasing HIV RNA values.

All 5 patients were retreated (three consecutive doses monthly starting between days 120-150). Following retreatment a statistically significant (P=0.0006) fall in HIV RNA measurements were observed by Day >250.

Statistical analysis was performed using paired t-Test,
Wilcoxon Signed Rank Test and Mann-Whitney
Rank Sum Test.

START DATE: 06/13/95

5 **END DATE: Open**

Table 9.5
Patient Group 2

TEST	HIV-RNA QUANTITATIVE BY PCR						
	DAY 1	DAY 7	DAY 21-28	DAY 60-90	Day 180-210	Day 240-300	DAY >380
10 Mean	21911	10643.2	10962.6	15231.8	18424	9385.2	8217
Std error	5003.7	3244.3	2222.5	7385.9	5473.5	5436.3	5135
Maximum	41182	21223	17679	41922	35129	30412	36412
Minimum	12292	4448	3790	2984	4017	1036	756
15 Median	18976	6317	11570	6787	16854	4708	4926

Table 9.6
Patient Group 3

TEST	QUANTITATIVE CD4/mm ³						
	DAY 1	DAY 7	DAY 21-28	DAY 60-90	Day 180-210	Day 240-300	DAY >380
20 Mean	25	30.8	13.8	35	40.4	59.6	67
Std error	6.47	8.16	3.01	9.66	13.39	25.72	33.74
Maximum	42	51	20	60	82	154	178
Minimum	9	8	3	10	8	13	16.01
25 Median	26	24	16	42	28	36	42.12

Table 9.7
Patient Group 3

TEST	QUANTITATIVE CD8/mm ³						
	DAY 1	DAY 7	DAY 21-28	DAY 60-90	Day 180-210	Day 240-300	DAY >380
Mean	705.6	633.8	486.4	681.4	570.8	826.6	856.24
Std error	137.8	168.2	86	229	120.6	200.9	226
Maximum	1152	1037	700	1380	756	1320	1346
Minimum	444	220	260	180	101	169	556
Median	585	828	540	720	638	812	843

Patient Group 4

Patient n = 7

Primary Objective: Evaluate toxicity and efficacy of HRG214 treatment of HIV infection at a daily dose of 1.5 mg/kg/day for 28 days with IFN inducer on days 1-7 and 21-23. Clinical follow-up will continue for 3 years. Patients will have retreat options with recurrence.

End Points: Normalization of clinical parameters and laboratory parameters including improvement in OI, incidence of infections, wasting syndrome, etc., in abnormal blood chemistry and hematology, CD4 and CD8, reductions in HIV-RNA quantitated by PCR.

Follow-up period 3 years

Follow-up period to date = >405 days

Study Demographics: Patient n=7; Start Date - 8/25/95; As of day 390, Survivors=7; Deaths=0; Lost to follow up=0.

Patient Demographics: HIV positive patients with CD4 number >200 without AIDS defining criterion.

Treatment Drug(s): 1.5 mg/kg/day for 28 days. Patients will have retreat options with recurrence.

Table 9.8
Patient Group 4

HIV-RNA QUANTITATIVE BY PCR					
TEST	DAY 1	DAY 21-28	DAY 60-90	DAY 180-210	DAY 330-390
Mean	6078.7	964.3	899.7	658	386.2
Std error	949.4	639.6	199.1	544	257
Maximum	7936	2207	1257	1202	983
Minimum	4808	80	569	114	54.1
Median	5492	606	873	658	432

Table 9.9
Patient Group 4

QUANTITATIVE CD4/mm ³					
TEST	DAY 1	DAY 21-28	DAY 60-90	DAY 180-210	DAY 330-390
Mean	315	302.7	361.3	409.3	486.5
Std error	72.6	70.3	66.8	72.9	71.8
Maximum	429	440	460	540	611
Minimum	180	208	234	288	301
Median	336	260	390	400	435

Table 9.10
Patient Group 4

TEST	QUANTITATIVE CD8/mm ³				
	DAY 1	DAY 21-28	DAY 60-90	DAY 180-210	DAY 330-390
Mean	970.7	867.7	1016	1094	1164
Std error	247.7	158.7	378.8	229.5	235.2
Maximum	1464	1180	1770	1550	1672
Minimum	685	663	576	820	921
Median	763	760	702	912	986

10 **Patient Group 5**

Patient n = 6

Primary Objective: Evaluate toxicity and efficacy of HRG214 treatment. Clinical follow-up will continue for 3 years. Patients will have retreat options with recurrence.

15 **End Points:** Normalization of clinical parameters and laboratory parameters including improvement in OI, incidence of infections, wasting syndrome, etc. in abnormal blood chemistry and hematology, CD4 and CD8, reductions in HIV-RNA quantitated by PCR

Follow-up period 3 years

Follow-up period to date = > 469 days

20 Start date of 6/13/95; as of day 270, Survivors = 2; Deaths = 4 (2 deaths between 180-210, 1 death between 240-270; one death after 270); Lost to follow up = 0

25 Patient Population: HIV positive patients with AIDS defining criteria including CD4 < 200/mm³ blood and disseminated Kaposi's sarcoma. Patients were treated with systemic chemotherapy. Two patients died between 30 days 180-210 and two patients died after day 240.

HIV-RNA quantitated by PCR demonstrated reductions at days 60-90, 120-150, 180-210 and 240-270 ($p=0.018$).

Statistical analysis was performed using paired t Test
Wilcox, Signed Rank Test and Mann-Whitney

5 Rank Sum Test.

Table 9.11
Patient Group 5

HIV-RNA QUANTITATIVE BY PCR						
TEST	DAY 1	DAY 21-28	DAY 60-90	Day 120-150	Day 180-210	DAY 240-270
10 Mean	12483.3	16973.7	8373.7	8237.8	8287	4717.5
Std error	3159.1	6889.1	3081.8	2152.3	2466.6	3609.5
Maximum	20233	46586	19514	15249	15570	8327
Minimum	442	1242	490	1358	4708	1108
15 Median	13682	14510	7027	7392	6435	4717.5

Table 9.12
Patient Group 5

QUANTITATIVE CD4/mm ³						
TEST	DAY 1	DAY 21-28	DAY 60-90	Day 120-150	Day 180-210	DAY 240-270
20 Mean	43.7	20.5	22.3	17.5	12.6	36
Std error	31.46	12.04	8.45	6.76	4.12	Undefined
Maximum	200	80	48	48	24	36
Minimum	4	4	2	2	4	36
25 Median	12	9.5	17	11	8	36

Table 9.13
Patient Group 5

TEST	QUANTITATIVE CD8/mm ³					
	DAY 1	DAY 21-28	DAY 60-90	Day 120-150	Day 180-210	DAY 240-270
Mean	476.3	303.5	415.8	371	326.4	676
Std error	152.9	62.7	159.1	100.7	96.2	Undefined
Maximum	1170	540	1152	710	618	676
Minimum	98	86	92	62	101	676
Median	352	271.5	293.5	358	245	676

Bibliography

1. H. Mitsuya, S. Broder, *Nature* **325**, 773-778 (1987).
2. *The Molecular Biology of Tumor Viruses*, J. Tooze, et al., Eds. (1973).
- 5 3. *RNA Tumor Viruses*. R. Weiss, Ed. (1982).
4. F. Gonzalez-Scarano, R.E. Shoppe, C.E. Calisher, N. Nathanson, *Virology* **120**, 42-53 (1982).
5. S. Matsuno, S. Inouye, *Infection and Immunity* **39**, 155-158 (1983).
- 10 6. J. Mathews, J. Roehrig, *The Journal of Immunology* **129**, 2763-2767 (1982).
7. M. Robert-Guroff, M. Brown, R. Gallo, *Nature* **316**, 72-74 (1985).
8. R. Weiss, et al., *Nature* **316**, 69-72 (1985).
- 15 9. T. Matthews, et al., *Proceedings of the National Academy of Sciences* **83**, 9709-9713 (1986).
10. W. Robey, et al., *Proceedings of the National Academy of Sciences* **83**, 7023-7027 (1986).
11. L. Lasky, et al., *Science* **233**, 209-212 (1986).
- 20 12. D. Zagury, et al., *Nature* **326**, 249-250 (1987).
13. J. McDougal, et al., *Science* **231**, 382-385 (1986).
14. S. Putney, et al., *Science* **234**, 1392-13905 (1986).
15. S. Norley, R. Kurth, *The Retroviridae*, J. Levy, Ed. (Plenum Press, 1994), vol. 5.
- 25 16. J. Carlson, *JAMA* **260**, 674-679 (1988).
17. J. Lange, et al., *British Medical Journal* **292**, 228-230 (1986).
18. J. McDougal, et al., *Journal of Clinical Investigation* **80**, 316-324 (1987).

19. A. Amadori, A. De Rossi, G. Faulker-Valle, I. Chieco-Bianchi, *Clinical Immunology and Immunopathology* **46**, 342-351 (1988).
- 5 20. A. Amadori, et al., *The Journal of Immunology* **89**, 2146-2152 (1989).
21. E. Barker, S. W. Barnett, L. Stamataos, J. A. Levy, in *The Viruses: The Retroviridae* J.A. Levy, Ed. (Plenum Press, New York and London, 1995), vol. 4, pp. 1-7.
- 10 22. J. A. Levy, in *HIV and the Pathogenesis of AIDS* A. Press, Ed. (ASM Press, Washington, DC, 1994) pp. 1-5.
23. D. F. Nixon, K. Broliden, G. Ogg, P.-A. Broliden, *Immunology* **76**, 515-534 (1992).
- 15 24. P. Linsley, J. Ledbetter, E. Kinney-Thomas, S.-L. Hu, *J Virology* **62**, 3695-3702 (1988).
- 25 25. M. Thali, et al., *J Virology* **66**, 5635-5641 (1992).
- 20 26. A. Benjouard, J. Glucksmann, H. Roizat, L. Montagnier, E. Bahraoui, *J. Virology* **66**, 2473-83 (1992).
27. T. Chanh, et al., *The EMBO Journal* **5**, 3065-71 (1986).
28. J. Homsy, M. Meyer, J. Levy, *J. Virology* **64**, 1437-40 (1990).
- 25 29. M. Tremblay, et al. *J Immunology* **145**, 2896-2901 (1990).
- 30 30. R. Garry, *Science* **250**, 1127-1129 (1990).
31. M. Mackett, G. Smith, B. Moss, *Proc. Natl. Acad. Sci. USA* **79**, 7415-7419 (1982).
- 30 32. D. Panicali, E. Paoletti, *Proc. Natl. Acad. Sci. USA* **79**, 4927-4931 (1982).
33. S.-L. Hu, S. Kosowski, J. Darymple, *Nature* **320**, 537-540 (1986).
- 35 34. S. Chakrabarti, M. Robert-Guroff, F. Wong-Staal, R. Gallo, B. Moss, *Nature* **320**, 535-537 (1986).

35. D. G. Kleid, et al., *Science* **214**, 1125-1129 (1981).
 36. C. Cabradilla, et al., *Bio/Technology* **4**, 128-133 (1986).
 - 5 37. *Current Protocols in Immunology* (John Wiley & Sons, 1995).
 38. *Remington's Pharmaceutical Science* (Mack Publishing Co, Easton, PA, ed. 15th, 1990).
 - 10 39. B. Karpovsky, J. Titus, D. Stephany, D. Segal, *Journal of Experimental Medicine* **160**, 1686-1701 (1984).
 40. P. Cuatrecasas, *Advances in Enzymology* **36**, 29 (1972).
 - 15 41. P. Tijssen, *Practice and Theory of Enzyme Immunoassay* (1985).
 42. Stewart, Young, *Solid Phase Peptide Synthesis* (Pierce Chemical Co, ed. 2nd, 1984).
 43. J. Tam, et al., *Journal American Chemical Society* **105**, 6442 (1983).
 - 20 44. Maniatis, *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Laboratory, 1982).
 45. Z. Grabarek, J. Gergely, *Analytical Biochemistry* **185** (1990).
 - 25 46. J. Staros, R. Wright, D. Swingle, *Analytical Biochemistry* **156**, 220-222 (1986).
 47. R. Timkovich, *Analytical Biochemistry* **79**, 135-143 (1977).
 48. F. Gelder, et al. *Annals of Surgery*, 591-599 (1991).
 49. M. Fung, et al., *J. Virology*, **66**, 848-856 (1992)
-

In the claims:

1. A composition comprising HIV proteins isolated from a lysate of an HIV isolate which has been treated to remove human HLA class I and class II antigens present in said lysate, wherein said proteins have been
5 deglycosylated and wherein said proteins comprise at least one epitope region which does not elicit an immune response in man when encountered by infection or environmental exposure but does elicit an immune response in at least one non-human mammalian species.
 2. A composition in accordance with claim 1, wherein said epitope region encompasses a neutralizing or inactivating region of said HIV protein.
 3. A composition in accordance with claim 1, wherein said epitope region has an amino acid sequence which corresponds to or immunologically mimics a portion of a human protein amino acid sequence.
 4. A composition in accordance with claim 1, which has been enriched for said epitope region(s).
 5. A composition in accordance with claim 4, wherein said epitope region(s) comprises at least about 25% of said protein.
 6. A composition in accordance with claim 5, wherein said epitope region(s) comprises between about 50% and about 95% of said protein.
 7. A composition in accordance with claim 1, which comprises a mixture of lysates from different HIV isolates.
 8. A composition in accordance with claim 1, which comprises a mixture of lysates from HIV_{1HN}, HIV_{1BAL}, and HIV_{2NZ}.
 9. A composition in accordance with claim 1, wherein said epitope region corresponds to or mimics at least one epitope region of proteins of HIV isolate
-

5 HIV1_{SF2} which does not elicit an immune response in man when encountered by infection or environmental exposure but does elicit an immune response in at least one other mammalian species.

10. A composition in accordance with claim 9, wherein said epitope region corresponds to or mimics an epitope region of at least one of the following HIV1_{SF2} proteins:

- 5 (a) envelope gp120 external glycoprotein;
(b) envelope gp41 transmembrane glycoprotein;
(c) reverse transcriptase;
(d) protease p10; or
(e) gag precursor.

11. A composition in accordance with claim 10, wherein at least one of said epitope regions of HIV_{SF2} proteins comprises:

- 5 (a) a region extending from amino acid residue 4 through amino acid residue 27 of gp120 glycoprotein;
(b) a region extending from amino acid residue 54 through amino acid residue 76 of gp120 glycoprotein;
10 (c) a region extending from amino acid residue 502 through amino acid residue 541 of gp41 transmembrane glycoprotein;
(d) a region extending from amino acid residue 254 through amino acid residue 295 of reverse
15 transcriptase heterodimer p66/55;
(e) a region extending from amino acid residue 69 through 94 of protease p10;
(f) a region extending from amino acid residue 166 through amino acid residue 181 of gag gene protein
20 p24;
-

- (g) a region extending from amino acid residue 390 through amino acid residue 410 and amino acid residue 438 through 443 of gag gene protein p7;
- (h) a region extending from amino acid residue 2 through amino acid residue 23 of gag gene protein p17; or
- (i) a region extending from amino acid residue 89 through amino acid residue 122 of gag gene protein p17.
- 25
12. A composition in accordance with claim 1, which further comprises an adjuvant.
13. A composition in accordance with claim 12, wherein said adjuvant comprises a carrier molecule to which the HIV protein is coupled.
14. A composition in accordance with claim 13, wherein said carrier molecule comprises poly-L-lysine, keyhole limpet hemocyanin, thyroglobulin, an albumin or tetanus toxoid.
15. A composition in accordance with claim 13, wherein said carrier molecule comprises multiple repeats of a glycopeptide.
16. A composition in accordance with claim 15, wherein said carrier molecule comprises multiple repeats of muramyl dipeptide.
17. A composition in accordance with claim 16, wherein said multiple repeats of muramyl dipeptide are crosslinked.
18. A composition in accordance with claim 17, wherein said multiple repeats of muramyl dipeptide comprise a terminal dipeptide of L-alanine-D-isoglutamine.
19. A composition comprising a synthetic peptide which comprises an epitope region which corresponds to or mimics a neutralizing or inactivating region of an HIV protein, wherein said peptide does not elicit an

immune response in humans when encountered by infection or environmental exposure but does elicit an immune response in at least one non-human mammalian species.

20. A composition in accordance with claim 19, wherein said epitope region has an amino acid sequence which corresponds to or mimics a portion of a human protein.

21. A composition in accordance with claim 19, wherein at least one amino acid within said epitope region is modified to enhance MHC interactions or the immune response obtained following administration of said peptide to a non-human mammal.

22. A composition in accordance with claim 21, wherein at least one amino acid is modified so as to create an amphipathic helix with said epitope region bracketed between hydrophilic amino acids and hydrophobic amino acids.

23. A composition in accordance with claim 19, comprising a mixture of said synthetic peptides, wherein said peptides comprise epitope regions which correspond to or mimic more than one neutralizing or inactivating region of HIV proteins.

24. A composition in accordance with claim 19, wherein said epitope region corresponds to or mimics a neutralizing or inactivating region of a protein of HIV isolate HIV1_{SF2}.

25. A composition in accordance with claim 23, wherein said epitope regions correspond to or mimic more than one neutralizing or inactivating region of proteins of HIV isolate HIV1_{SF2}.

26. A composition in accordance with claim 24 or 25, wherein said HIV1_{SF2} protein comprises:

- (a) envelope gp120 external glycoprotein;
- (b) envelope gp41 transmembrane glycoprotein;

- (c) reverse transcriptase;
- (d) protease p10; or
- (e) gag precursor.

27. A composition in accordance with claim 26, wherein said neutralizing or inactivating region of HIV_{SF2} protein comprises:

- (a) a region extending from amino acid residue 4
5 through amino acid residue 27 of gp120 glycoprotein;
- (b) a region extending from amino acid residue 54 through amino acid residue 76 of gp120 glycoprotein;
- (c) a region extending from amino acid residue 502
10 through amino acid residue 541 of gp41 transmembrane glycoprotein;
- (d) a region extending from amino acid residue 254 through amino acid residue 295 of reverse transcriptase heterodimer p66/55;
- (e) a region extending from amino acid residue 69
15 through 94 of protease p10;
- (f) a region extending from amino acid residue 166 through amino acid residue 181 of gag gene protein p24;
- (g) a region extending from amino acid residue 390
20 through amino acid residue 410 and amino acid residue 438 through 443 of gag gene protein p7;
- (h) a region extending from amino acid residue 2 through amino acid residue 23 of gag gene protein p17; or
25
- (i) a region extending from amino acid residue 89 through amino acid residue 122 of gag gene protein p17.

28. A composition in accordance with claim 19, which further comprises an adjuvant.

29. A composition in accordance with claim 28, wherein said adjuvant comprises a carrier molecule to which the HIV peptide is coupled.

30. A composition in accordance with claim 29, wherein said carrier molecule comprises poly-L-lysine, keyhole limpet hemocyanin, thyroglobulin, an albumin or tetanus toxoid.

31. A composition in accordance with claim 29, wherein said carrier molecule comprises multiple repeats of a glycopeptide.

32. A composition in accordance with claim 31, wherein said carrier molecule comprises multiple repeats of muramyl dipeptide.

33. A composition in accordance with claim 32, wherein said multiple repeats of muramyl dipeptide are crosslinked.

34. A composition in accordance with claim 33, wherein said multiple repeats of muramyl dipeptide comprise a terminal dipeptide of L-alanine-D-isoglutamine.

35. A method of identifying a neutralizing or inactivating region of an HIV protein, wherein said neutralizing or inactivating region does not elicit an immune response in man when encountered by infection or environmental exposure but does elicit an immune response in a non-human mammal, which comprises:

(a) extracting HIV proteins from a lysate of an HIV strain;

(b) immunizing a non-human mammal with said extract;

(c) obtaining antisera from said immunized mammal;

(d) employing said antisera in a competitive immunoassay with human HIV antisera to identify regions of HIV proteins which are recognized by

antibodies in said antisera but not recognized by antibodies in said human antisera; and

(e) determining which of said regions is a neutralizing or inactivating region.

36. A method in accordance with claim 35, wherein said neutralizing or inactivating region comprises or is homologous to one of the following regions of a protein of HIV isolate HIV_{1SF2}:

- 5 (a) a region extending from amino acid residue 4 through amino acid residue 27 of gp120;
- (b) a region extending from amino acid residue 54 through amino acid residue 76 of gp120;
- (c) a region extending from amino acid residue 502 through amino acid residue 541 of gp41;
- 10 (d) a region extending from amino acid residue 254 through amino acid residue 295 of reverse transcriptase heterodimer p66/55;
- (e) a region extending from amino acid residue 69 through 94 of protease p10;
- 15 (f) a region extending from amino acid residue 166 through amino acid residue 181 of gag gene protein p24;
- (g) a region extending from amino acid residue 390 through amino acid residue 410 and amino acid residue 438 through 443 of gag gene protein p7;
- 20 (h) a region extending from amino acid residue 2 through amino acid residue 23 of gag gene protein p17; or
- 25 (i) a region extending from amino acid residue 89 through amino acid residue 122 of gag gene protein p17.

37. A method for obtaining antibodies which react with an epitope on a neutralizing or inactivating region of an HIV protein, wherein said neutralizing or inactivating region of said protein fails to elicit an

5 immune response in man when encountered by infection or environmental exposure but does elicit an immune response in a non-human mammal which comprises:

- (a) isolating proteins from a lysate of an HIV isolate;
- 10 (b) identifying an epitope on at least one of said proteins which has an amino acid sequence which corresponds to or mimics the amino acid sequence of a neutralizing or inactivating region which fails to elicit an immune response in man when
- 15 encountered by infection or environmental exposure but does elicit an immune response in a non-human mammal;
- (c) combining said proteins with a physiologically acceptable carrier;
- 20 (d) immunizing a non-human mammalian host with said proteins and carrier; and
- (e) obtaining antibodies to said epitope from said immunized host.

38. A method in accordance with claim 37, wherein said lysate is treated to remove HLA class I and class II antigens.

39. A method in accordance with claim 37, wherein said proteins are deglycosylated prior to being combined with said physiological carrier.

40. A method in accordance with claim 37, wherein the amino acid sequence of said epitope corresponds to or mimics a portion of a human protein amino acid sequence.

41. A method in accordance with claim 37, wherein said protein is conjugated with an adjuvant prior to being combined with a physiologically acceptable carrier.

42. A method in accordance with claim 41, wherein said adjuvant comprises a macromolecular carrier.

43. A method in accordance with claim 42, wherein said macromolecular carrier comprises multiple repeats of muramyl dipeptide.

44. A method in accordance with claim 43, wherein said multiple repeats of muramyl dipeptide comprise a terminal dipeptide of L-alanine-D-isoglutamine.

45. A method in accordance with claim 37, wherein said proteins comprise epitopes which correspond to or mimic more than one neutralizing or inactivating region.

46. A method in accordance with claim 37, wherein said neutralizing or inactivating region comprises a portion of an envelope glycoprotein or transmembrane protein.

47. A method in accordance with claim 45, wherein at least one of said neutralizing or inactivating regions comprises a portion of an envelope glycoprotein or transmembrane protein.

48. A method in accordance with claim 47, which further comprises a neutralizing or inactivating region of protease p10.

49. A method in accordance with claim 37, wherein said epitope corresponds to or mimics an epitope region of HIV1_{SF2} which comprises:

- 5 (a) a region extending from amino acid residue 4 through amino acid residue 27 of gp120;
- (b) a region extending from amino acid residue 54 through amino acid residue 76 of gp120;
- (c) a region extending from amino acid residue 502 through amino acid residue 541 of gp41;
- 10 (d) a region extending from amino acid residue 254 through amino acid residue 295 of reverse transcriptase heterodimer p66/55;
- (e) a region extending from amino acid residue 69 through 94 of protease p10;

15 (f) a region extending from amino acid residue 166 through amino acid residue 181 of gag gene protein p24;

(g) a region extending from amino acid residue 390 through amino acid residue 410 and amino acid
20 residue 438 through 443 of gag gene protein p7;

(h) a region extending from amino acid residue 2 through amino acid residue 23 of gag gene protein p17; or

(i) a region extending from amino acid residue 89
25 through amino acid residue 122 of gag gene protein p17.

50. A method in accordance with claim 49, wherein said proteins comprise epitopes which correspond to or mimic more than one neutralizing or inactivating region and said epitopes correspond to or mimic two or more of
5 said epitope regions of HIV_{SF2}.

51. A method in accordance with claim 37 or 45, wherein said proteins have been enriched for said epitope(s).

52. A method in accordance with claim 45, wherein said epitopes are present in relative proportions which range from about 1:1 to a maximum difference in amount between any two epitopes of 10:1.

53. A method for obtaining antibodies which react with an epitope on a neutralizing or inactivating region of an HIV protein, wherein said neutralizing or inactivating region of said protein fails to elicit an
5 immune response in man when encountered by infection or environmental exposure but does elicit an immune response in a non-human mammal, which comprises:

(a) synthesizing a peptide having an amino acid sequence which corresponds to or mimics an epitope
10 on a neutralizing or inactivating region of an HIV protein, wherein said region fails to elicit an

immune response in man when encountered by infection or environmental exposure but does elicit an immune response in a non-human mammal;

- 15 (b) combining said peptide with a physiologically acceptable carrier;
- (c) immunizing a non-human mammalian host with said peptide and carrier; and
- 20 (d) obtaining antibodies to said epitope from said immunized host.

54. A method in accordance with claim 53, wherein said peptide has an amino acid sequence which mimics a portion of a human protein amino acid sequence.

55. A method in accordance with claim 53, wherein said peptide is conjugated with an adjuvant prior to being combined with said physiologically acceptable carrier.

56. A method in accordance with claim 55, wherein said adjuvant comprises a macromolecular carrier.

57. A method in accordance with claim 56, wherein said macromolecular carrier comprises multiple repeats of muramyl dipeptide.

58. A method in accordance with claim 57, wherein said multiple repeats of muramyl dipeptide comprise a terminal dipeptide of L-alanine-D-isoglutamine.

59. A method in accordance with claim 53, which comprises a mixture of peptides, each of which has an amino acid sequence which corresponds to or mimics an epitope on a neutralizing or inactivating region of an HIV protein, wherein said region fails to elicit an immune response in man when encountered by infection or environmental exposure but does elicit an immune response in a non-human mammal.
- 5

60. A method in accordance with claim 53, wherein said peptide has an amino acid sequence which corresponds to or mimics a neutralizing or inactivating

5 region which comprises a portion of an envelope glycoprotein or transmembrane protein.

61. A method in accordance with claim 59, wherein at least one of peptides has an amino acid sequence which corresponds to or mimics a neutralizing or inactivating region which comprises a portion of an envelope glycoprotein or transmembrane protein.

62. A method in accordance with claim 61, which further comprises a peptide which has an amino acid sequence which corresponds to or mimics a neutralizing or inactivating region of protease p10.

63. A method in accordance with claim 53, wherein the amino acid sequence of said peptide corresponds to or mimics the amino acid sequence of an epitope on a neutralizing or inactivating region of a protein of HIV_{1SF2} which comprises:

- (a) a region extending from amino acid residue 4 through amino acid residue 27 of gp120;
- (b) a region extending from amino acid residue 54 through amino acid residue 76 of gp120;
- 10 (c) a region extending from amino acid residue 502 through amino acid residue 541 of gp41;
- (d) a region extending from amino acid residue 254 through amino acid residue 295 of reverse transcriptase heterodimer p66/55;
- 15 (e) a region extending from amino acid residue 69 through 94 of protease p10;
- (f) a region extending from amino acid residue 166 through amino acid residue 181 of gag gene protein p24;
- 20 (g) a region extending from amino acid residue 390 through amino acid residue 410 and amino acid residue 438 through 443 of gag gene protein p7;

25 (h) a region extending from amino acid residue 2 through amino acid residue 23 of gag gene protein p17; or

(i) a region extending from amino acid residue 89 through amino acid residue 122 of gag gene protein p17.

64. A method in accordance with claim 59, wherein said peptides correspond to or mimic amino acid sequences of at least two epitopes on neutralizing or inactivating regions of HIV₁_{sf2} proteins, said regions comprising:

- 5 (a) a region extending from amino acid residue 4 through amino acid residue 27 of gp120;
- (b) a region extending from amino acid residue 54 through amino acid residue 76 of gp120;
- 10 (c) a region extending from amino acid residue 502 through amino acid residue 541 of gp41;
- (d) a region extending from amino acid residue 254 through amino acid residue 295 of reverse transcriptase heterodimer p66/55;
- 15 (e) a region extending from amino acid residue 69 through 94 of protease p10;
- (f) a region extending from amino acid residue 166 through amino acid residue 181 of gag gene protein p24;
- 20 (g) a region extending from amino acid residue 390 through amino acid residue 410 and amino acid residue 438 through 443 of gag gene protein p7;
- (h) a region extending from amino acid residue 2 through amino acid residue 23 of gag gene protein p17; or
- 25 (i) a region extending from amino acid residue 89 through amino acid residue 122 of gag gene protein p17.

65. A method in accordance with claim 59, wherein said peptides are present in relative proportions which range from about 1:1 to a maximum difference in amount between any two peptides of 10:1.

66. An antibody which recognizes and reacts with an epitope which corresponds to or mimics an epitope on a neutralizing or inactivating region of an HIV protein, wherein said neutralizing or inactivating
5 region of said protein fails to elicit an immune response in man when encountered by infection or environmental exposure.

67. An antibody in accordance with claim 66, wherein said epitope has an amino acid sequence which corresponds to or immunologically mimics a portion of a human protein amino acid sequence or a neurotoxin
5 protein amino acid sequence.

68. An antibody in accordance with claim 66, wherein said protein comprises carbohydrate-depleted envelope precursor gp160, gp120 glycoprotein or gp 41 transmembrane glycoprotein.

69. An antibody in accordance with claim 66, wherein said protein comprises a carbohydrate depleted gag precursor p55 or cleaved gag products p17, p24 or p7.

70. An antibody in accordance with claim 66, wherein said protein comprises carbohydrate-depleted protease p10 or reverse transcriptase heterodimer p66/55.

71. An antibody in accordance with claim 67, wherein said human protein comprises alpha fetoprotein, aspartyl protease, deoxyuridine 5'-triphosphate nucleotidohydrolase, eosinophil cationic protein or
5 eosinophil-derived neurotoxin.

72. An antibody in accordance with claim 66, wherein said antibody recognizes an epitope which

corresponds to or mimics an epitope on one of the following neutralizing or inactivating regions of HIV isolate HIV_{1SF2}:

- 5 (a) a region extending from amino acid residue 4 through amino acid residue 27 of gp120;
- (b) a region extending from amino acid residue 54 through amino acid residue 76 of gp120;
- 10 (c) a region extending from amino acid residue 502 through amino acid residue 541 of gp41;
- (d) a region extending from amino acid residue 254 through amino acid residue 295 of reverse transcriptase heterodimer p66/55;
- 15 (e) a region extending from amino acid residue 69 through 94 of protease p10;
- (f) a region extending from amino acid residue 166 through amino acid residue 181 of gag gene protein p24;
- 20 (g) a region extending from amino acid residue 390 through amino acid residue 410 and amino acid residue 438 through 443 of gag gene protein p7;
- (h) a region extending from amino acid residue 2 through amino acid residue 23 of gag gene protein p17; or
- 25 (i) a region extending from amino acid residue 89 through amino acid residue 122 of gag gene protein p17.

73. A combination of at least two antibodies, each of which recognizes and reacts with an epitope which corresponds to or mimics an epitope on a neutralizing or inactivating region of an HIV protein,
5 wherein said neutralizing or inactivating region of said protein fails to elicit an immune response in man when encountered by infection or environmental exposure.

74. A combination of antibodies in accordance with claim 73, wherein each of said antibodies recognizes and reacts with an epitope which has an amino acid sequence which corresponds to or
5 immunologically mimics a portion of a human protein amino acid sequence or a neurotoxin protein amino acid sequence.

75. A combination of antibodies in accordance with claim 73, wherein at least one of said antibodies recognizes and reacts with an epitope which corresponds to or mimics an epitope on a neutralizing or
5 inactivating region of carbohydrate-depleted envelope precursor gp160, gp120 glycoprotein or gp 41 transmembrane glycoprotein.

76. A combination of antibodies in accordance with claim 73, wherein at least one of said antibodies recognizes and reacts with an epitope which corresponds to or mimics an epitope on a neutralizing or
5 inactivating region of carbohydrate-depleted gag precursor p55 or cleaved gag products p17, p24 or p7.

77. A combination of antibodies in accordance with claim 73, wherein at least one of said antibodies recognizes and reacts with an epitope which corresponds to or mimics an epitope on a neutralizing or
5 inactivating region of carbohydrate-depleted protease p10 or reverse transcriptase heterodimer p66/55.

78. A combination of antibodies in accordance with claim 74, wherein said human protein comprises alpha fetoprotein, aspartyl protease, deoxyuridine 5'-triphosphate nucleotidohydrolase, eosinophil cationic
5 protein or eosinophil-derived neurotoxin.

79. A combination of antibodies in accordance with claim 73, wherein at least one of said antibodies recognizes an epitope which corresponds to or mimics an

- epitope on one of the following neutralizing or
- 5 inactivating regions of HIV isolate HIV1_{SF2}:
- (a) a region extending from amino acid residue 4 through amino acid residue 27 of gp120;
 - (b) a region extending from amino acid residue 54 through amino acid residue 76 of gp120;
 - 10 (c) a region extending from amino acid residue 502 through amino acid residue 541 of gp41;
 - (d) a region extending from amino acid residue 254 through amino acid residue 295 of reverse transcriptase heterodimer p66/55;
 - 15 (e) a region extending from amino acid residue 69 through 94 of protease p10;
 - (f) a region extending from amino acid residue 166 through amino acid residue 181 of gag gene protein p24;
 - 20 (g) a region extending from amino acid residue 390 through amino acid residue 410 and amino acid residue 438 through 443 of gag gene protein p7;
 - (h) a region extending from amino acid residue 2 through amino acid residue 23 of gag gene protein p17; or
 - 25 (i) a region extending from amino acid residue 89 through amino acid residue 122 of gag gene protein p17.

80. A combination of antibodies in accordance with claim 79, which comprises antibodies which recognize an epitope which corresponds to or mimics an epitope on each of the following neutralizing or

- 5 inactivating regions of HIV isolate HIV1_{SF2}:
- (a) a region extending from amino acid residue 4 through amino acid residue 27 of gp120;
 - (b) a region extending from amino acid residue 54 through amino acid residue 76 of gp120; and

10 (c) a region extending from amino acid residue 502
through amino acid residue 541 of gp41.

81. A combination of antibodies in accordance
with claim 79, which comprises antibodies which
recognize an epitope which corresponds to or mimics an
epitope on each of the following neutralizing or
5 inactivating regions of HIV isolate HIV1_{SF2}:

- (a) a region extending from amino acid residue 4
through amino acid residue 27 of gp120;
- (b) a region extending from amino acid residue 54
through amino acid residue 76 of gp120;
- 10 (c) a region extending from amino acid residue 502
through amino acid residue 541 of gp41; and
- (d) a region extending from amino acid residue 69
through 94 of protease p10.

82. A combination of antibodies in accordance
with claim 79, which comprises antibodies which
recognize epitopes which correspond to or mimic
epitopes on each of the following neutralizing or
5 inactivating regions of HIV isolate HIV1_{SF2}:

- (a) a region extending from amino acid residue 4
through amino acid residue 27 of gp120;
 - (b) a region extending from amino acid residue 54
through amino acid residue 76 of gp120;
 - 10 (c) a region extending from amino acid residue 502
through amino acid residue 541 of gp41;
- and at least one of the following neutralizing or
inactivating regions of HIV isolate HIV1_{SF2}:
- (d) a region extending from amino acid residue 69
15 through 94 of protease p10;
 - (e) a region extending from amino acid residue 166
through amino acid residue 181 of gag gene protein
p24;

- (f) a region extending from amino acid residue 390 through amino acid residue 410 and amino acid residue 438 through 443 of gag gene protein p7;
- (g) a region extending from amino acid residue 2 through amino acid residue 23 of gag gene protein p17; or
- (h) a region extending from amino acid residue 89 through amino acid residue 122 of gag gene protein p17
- (i) a region extending from amino acid residue 254 through 295 of reverse transcriptase heterodimer p66/55.
83. A combination of antibodies in accordance with claim 73, wherein said antibodies recognize epitopes which corresponds to or mimic epitopes on the following neutralizing or inactivating regions of HIV isolate HIV1_{SF2}:
- (a) a region extending from amino acid residue 4 through amino acid residue 27 of gp120;
- (b) a region extending from amino acid residue 54 through amino acid residue 76 of gp120;
- (c) a region extending from amino acid residue 502 through amino acid residue 541 of gp41;
- (d) a region extending from amino acid residue 254 through amino acid residue 295 of reverse transcriptase heterodimer p66/55;
- (e) a region extending from amino acid residue 69 through 94 of protease p10;
- (f) a region extending from amino acid residue 166 through amino acid residue 181 of gag gene protein p24;
- (g) a region extending from amino acid residue 390 through amino acid residue 410 and amino acid residue 438 through 443 of gag gene protein p7;

- 25 (h) a region extending from amino acid residue 2 through amino acid residue 23 of gag gene protein p17; and
- (i) a region extending from amino acid residue 89 through amino acid residue 122 of gag gene protein p17.

84. A composition comprising a combination of antibodies in accordance with claim 79 in a pharmaceutically acceptable carrier.

85. A composition comprising a combination of antibodies in accordance with claim 80 in a pharmaceutically acceptable carrier.

86. A composition comprising a combination of antibodies in accordance with claim 81 in a pharmaceutically acceptable carrier.

87. A composition comprising a combination of antibodies in accordance with claim 82 in a pharmaceutically acceptable carrier.

88. A composition comprising a combination of antibodies in accordance with claim 83 in a pharmaceutically acceptable carrier.

89. An antibody in accordance with claim 66, which is bound to a toxin or a radioactive material.

90. An antibody in accordance with claim 66, which is aggregated with a human T-cell activator.

91. A composition comprising an antibody in accordance with claim 66 in combination with aside-3'deoxythymidine, 2',3'-dideoxycytidine, 2',3'-dideoxy-2',3'-didehydrocytidine.

92. A composition comprising the proteins of claim 1 in combination with a pharmaceutically acceptable carrier.

93. A composition in accordance with claim 92, wherein said proteins are coupled to a macromolecular carrier.

94. A composition in accordance with claim 93, wherein said carrier is a microparticle of muramyl dipeptide.

95. A composition comprising one or more synthetic peptides of claim 19 in combination with a pharmaceutically acceptable carrier.

96. a composition in accordance with claim 95, wherein said peptides are coupled to a macromolecular carrier.

97. A composition in accordance with claim 96, wherein said carrier is a microparticle of muramyl dipeptide.

98. A method of inhibiting an infection of HIV in a human infected with the virus which comprises administering to said patient a therapeutically effective amount of a composition comprising one or
5 more antibodies each of which recognizes and reacts with an epitope which corresponds to or mimics an epitope on a neutralizing or inactivating region of an HIV protein, wherein said neutralizing or inactivating region of said protein fails to elicit an immune
10 response in man.

99. A method in accordance with claim 98, wherein said epitope has an amino acid sequence which corresponds to or immunologically mimics a portion of a human protein amino acid sequence when encountered by infection or environmental exposure.

100. A method in accordance with claim 98, wherein said protein comprises carbohydrate-depleted envelope precursor gp160, gp 120 glycoprotein or gp 41 transmembrane.

101. A method in accordance with claim 99, wherein said protein comprises carbohydrate-depleted gag precursor p55 or cleaved gag products p17, p24 or p7.

102. A method in accordance with claim 98, wherein said protein comprises carbohydrate-depleted protease p10 or reverse transcriptase heterodimer p66/55.

103. A method in accordance with claim 98, wherein said antibody is administered at a daily dose of about 0.1 to about 200 mg per kilogram of body weight.

104. A method in accordance with claim 98, wherein a combination of antibodies is administered and the ratio of each of said antibodies to one another does not differ by more than a factor of 10.

105. A method in accordance with claim 104, wherein the ratio of each of said antibodies to one another is approximately 1:1.

106. A method in accordance with claim 98 wherein said antibodies are conjugated to a macromolecular carrier.

107. A method in accordance with claim 106 wherein said carrier is a muramyl dipeptide microparticle.

108. A method in accordance with claim 98, wherein said antibody recognizes an epitope which corresponds to or mimics an epitope on one of the following neutralizing or inactivating regions of HIV isolate HIV1_{sf2}:

(a) a region extending from amino acid residue 4 through amino acid residue 27 of gp120;

(b) a region extending from amino acid residue 54 through amino acid residue 76 of gp120;

(c) a region extending from amino acid residue 502 through amino acid residue 541 of gp41;

(d) a region extending from amino acid residue 254 through amino acid residue 295 of reverse transcriptase heterodimer p66/55;

- 15 (e) a region extending from amino acid residue 69 through 94 of protease p10;
- (f) a region extending from amino acid residue 166 through amino acid residue 181 of gag gene protein p24;
- 20 (g) a region extending from amino acid residue 390 through amino acid residue 410 and amino acid residue 438 through 443 of gag gene protein p7;
- (h) a region extending from amino acid residue 2 through amino acid residue 23 of gag gene protein p17; or
- 25 (i) a region extending from amino acid residue 89 through amino acid residue 122 of gag gene protein p17.

109. A method in accordance with claim 108, wherein at least two antibodies are administered and each of said antibodies recognizes and reacts with an epitope which corresponds to or mimics an epitope on a neutralizing or inactivating region of an HIV protein, wherein said neutralizing or inactivating region of said protein fails to elicit an immune response in man when encountered by infection or environmental exposure.

110. A method in accordance with claim 109, wherein at least one of said antibodies recognizes and reacts with an epitope which corresponds to or mimics an epitope on a neutralizing or inactivating region of carbohydrate-depleted envelope precursor gp160, gp120 glycoprotein or gp41 transmembrane.

111. A method in accordance with claim 109, wherein at least one of said antibodies recognizes and reacts with an epitope which corresponds to or mimics an epitope on a neutralizing or inactivating region of carbohydrate-depleted gag precursor p55 or cleaved gag products p17, p24 or p7.

112. A method in accordance with claim 109,
wherein at least one of said antibodies recognizes and
reacts with an epitope which corresponds to or mimics
an epitope on a neutralizing or inactivating region of
5 carbohydrate-depleted protease p10 or reverse
transcriptase heterodimer p66/55.

113. A method in accordance with claim 109, which
comprises antibodies which recognize and react with
epitopes which correspond to or mimic epitopes from
each of the following neutralizing or inactivating
5 regions of HIV isolate HIV_{1SF2}:

- (a) a region extending from amino acid residue 4
through amino acid residue 27 of gp120;
- (b) a region extending from amino acid residue 54
through amino acid residue 76 of gp120;
- 10 (c) a region extending from amino acid residue 502
through amino acid residue 541 of gp41;
- (d) a region extending from amino acid residue 254
through amino acid residue 295 of reverse
transcriptase heterodimer p66/55;
- 15 (e) a region extending from amino acid residue 69
through 94 of protease p10;
- (f) a region extending from amino acid residue 166
through amino acid residue 181 of gag gene protein
p24;
- 20 (g) a region extending from amino acid residue 390
through amino acid residue 410 and amino acid
residue 438 through 443 of gag gene protein p7;
- (h) a region extending from amino acid residue 2
through amino acid residue 23 of gag gene protein
25 p17; or
- (i) a region extending from amino acid residue 89
through amino acid residue 122 of gag gene protein
p17.

114. A method for neutralizing or inactivating one or more essential steps in the life cycle of HIV in a patient infected with the virus which comprises administering to said patient a therapeutically effective amount of a composition comprising one or more antibodies each of which recognizes and reacts with an epitope which corresponds to or mimics an epitope on a neutralizing or inactivating region of an HIV protein, wherein said neutralizing or inactivating region of said protein fails to elicit an immune response in man.

115. A method in accordance with claim 112, wherein said epitope has an amino acid sequence which corresponds to or immunologically mimics a portion of a human protein amino acid sequence.

116. A method in accordance with claim 114, wherein said antibody recognizes an epitope which corresponds to or mimics an epitope on one of the following neutralizing or inactivating regions of HIV isolate HIV_{1SF2}:

(a) a region extending from amino acid residue 4 through amino acid residue 27 of gp120;

(b) a region extending from amino acid residue 54 through amino acid residue 76 of gp120;

(c) a region extending from amino acid residue 502 through amino acid residue 541 of gp41;

(d) a region extending from amino acid residue 254 through amino acid residue 295 of reverse transcriptase heterodimer p66/55;

(e) a region extending from amino acid residue 69 through 94 of protease p10;

(f) a region extending from amino acid residue 166 through amino acid residue 181 of gag gene protein p24;

- 20 (g) a region extending from amino acid residue 390
through amino acid residue 410 and amino acid
residue 438 through 443 of gag gene protein p7;
(h) a region extending from amino acid residue 2
through amino acid residue 23 of gag gene protein
25 p17; or
(i) a region extending from amino acid residue 89
through amino acid residue 122 of gag gene protein
p17.

117. A method in accordance with claim 115,
wherein at least two antibodies are administered and
each of said antibodies recognizes and reacts with an
epitope which corresponds to or mimics an epitope on a
5 neutralizing or inactivating region of an HIV protein,
wherein said neutralizing or inactivating region of
said protein fails to elicit an immune response in man.

118. A method in accordance with claim 114, which
comprises antibodies which recognize and react with
epitopes which correspond to or mimic epitopes from
each of the following neutralizing or inactivating
5 regions of HIV isolate HIV1_{SF2}:

- (a) a region extending from amino acid residue 4
through amino acid residue 27 of gp120;
(b) a region extending from amino acid residue 54
through amino acid residue 76 of gp120; and
10 (c) a region extending from amino acid residue 502
through amino acid residue 541 of gp41.

119. A method in accordance with claim 114, which
comprises antibodies which recognize and react with
epitopes which correspond to or mimic epitopes from
each of the following neutralizing or inactivating
5 regions of HIV isolate HIV1_{SF2}:

- (a) a region extending from amino acid residue 4
through amino acid residue 27 of gp120;

(b) a region extending from amino acid residue 54 through amino acid residue 76 of gp120;

10 (c) a region extending from amino acid residue 502 through amino acid residue 541 of gp41; and

(d) a region extending from amino acid residue 69 through 94 of protease p10.

120. A method in accordance with claim 114, which comprises antibodies which recognize and react with epitopes which correspond to or mimic epitopes from each of the following neutralizing or inactivating

5 regions of HIV isolate HIV1_{sf2}:

(a) a region extending from amino acid residue 4 through amino acid residue 27 of gp120;

(b) a region extending from amino acid residue 54 through amino acid residue 76 of gp120;

10 (c) a region extending from amino acid residue 502 through amino acid residue 541 of gp41;

(d) a region extending from amino acid residue 254 through amino acid residue 295 of reverse transcriptase heterodimer p66/55;

15 (e) a region extending from amino acid residue 69 through 94 of protease p10;

(f) a region extending from amino acid residue 166 through amino acid residue 181 of gag gene protein p24;

20 (g) a region extending from amino acid residue 390 through amino acid residue 410 and amino acid residue 438 through 443 of gag gene protein p7;

(h) a region extending from amino acid residue 2 through amino acid residue 23 of gag gene protein p17; or

25 (i) a region extending from amino acid residue 89 through amino acid residue 122 of gag gene protein p17.

121. A method in accordance with claim 114, wherein said antibodies are conjugated to a macromolecular carrier.

122. A method in accordance with claim 121, wherein said carrier comprises a muramyl dipeptide microparticle.

123. A method for preventing HIV infection in a patient who has been exposed to HIV which comprises administering to said patient a therapeutically effective amount of a composition comprising one or
5 more antibodies each of which recognizes and reacts with an epitope which corresponds to or mimics an epitope on a neutralizing or inactivating region of an HIV protein, wherein said neutralizing or inactivating region of said protein fails to elicit an immune
10 response in man when encountered by infection or environmental exposure.

124. A method in accordance with claim 119, wherein said epitope has an amino acid sequence which corresponds to or immunologically mimics a portion of a human protein amino acid sequence.

125. A method in accordance with claim 119, wherein said antibody recognizes an epitope which corresponds to or mimics an epitope on one of the following neutralizing or inactivating regions of HIV
5 isolate HIV1_{sf2}:

- (a) a region extending from amino acid residue 4 through amino acid residue 27 of gp120;
 - (b) a region extending from amino acid residue 54 through amino acid residue 76 of gp120;
 - 10 (c) a region extending from amino acid residue 502 through amino acid residue 541 of gp41;
 - (d) a region extending from amino acid residue 254 through amino acid residue 295 of reverse transcriptase heterodimer p66/55;
-

- 15 (e) a region extending from amino acid residue 69 through 94 of protease p10;
(f) a region extending from amino acid residue 166 through amino acid residue 181 of gag gene protein p24;
- 20 (g) a region extending from amino acid residue 390 through amino acid residue 410 and amino acid residue 438 through 443 of gag gene protein p7;
(h) a region extending from amino acid residue 2 through amino acid residue 23 of gag gene protein p17; or
- 25 (i) a region extending from amino acid residue 89 through amino acid residue 122 of gag gene protein p17.

126. A method in accordance with claim 125, wherein at least two antibodies are administered and each of said antibodies recognizes and reacts with an epitope which corresponds to or mimics an epitope on a neutralizing or inactivating region of an HIV protein, wherein said neutralizing or inactivating region of said protein fails to elicit an immune response in man.

127. A method in accordance with claim 125, which comprises antibodies which recognize and react with epitopes which correspond to or mimic epitopes from each of the following neutralizing or inactivating regions of HIV isolate HIV1_{SP2}:

- 5 (a) a region extending from amino acid residue 4 through amino acid residue 27 of gp120;
(b) a region extending from amino acid residue 54 through amino acid residue 76 of gp120; and
- 10 (c) a region extending from amino acid residue 502 through amino acid residue 541 of gp41.

128. A method in accordance with claim 125, which comprises antibodies which recognize and react with epitopes which correspond to or mimic epitopes

from each of the following neutralizing or inactivating
5 regions of HIV isolate HIV1_{SF2}:

- (a) a region extending from amino acid residue 4
through amino acid residue 27 of gp120;
- (b) a region extending from amino acid residue 54
through amino acid residue 76 of gp120;
- 10 (c) a region extending from amino acid residue 502
through amino acid residue 541 of gp41; and
- (d) a region extending from amino acid residue 69
through 94 of protease p10.

129. A method in accordance with claim 125, which
comprises antibodies which recognize and react with
epitopes which correspond to or mimic epitopes from
each of the following neutralizing or inactivating

5 regions of HIV isolate HIV1_{SF2}:

- (a) a region extending from amino acid residue 4
through amino acid residue 27 of gp120;
- (b) a region extending from amino acid residue 54
through amino acid residue 76 of gp120;
- 10 (c) a region extending from amino acid residue 502
through amino acid residue 541 of gp41;
- (d) a region extending from amino acid residue 254
through amino acid residue 295 of reverse
transcriptase heterodimer p66/55;
- 15 (e) a region extending from amino acid residue 69
through 94 of protease p10;
- (f) a region extending from amino acid residue 166
through amino acid residue 181 of gag gene protein
p24;
- 20 (g) a region extending from amino acid residue 390
through amino acid residue 410 and amino acid
residue 438 through 443 of gag gene protein p7;
- (h) a region extending from amino acid residue 2
through amino acid residue 23 of gag gene protein
25 p17; or

(i) a region extending from amino acid residue 89 through amino acid residue 122 of gag gene protein p17.

130. A method for detecting the presence of HIV in a biological fluid sample from an individual who may have been infected with HIV which comprises employing an antibody of claim 66 in an antibody-antigen assay in
5 which said antibody is combined with a sample of body fluid from said individual under conditions conducive to antibody-antigen complex formation and determining whether said antibody binds to an HIV antigen.

131. A method for detecting the presence of HIV in an individual who may have been infected with HIV which comprises employing an antibody of claim 66 in an enzyme immunoassay, wherein said antibody is conjugated
5 to an enzyme and contacted with a sample of body fluid from said individual under conditions conducive to antibody-antigen complex formation and determining whether said antibody binds to an HIV antigen.

132. A method for purifying protein containing at least one epitope which corresponds to or mimics an epitope of a neutralizing or inactivating region of an HIV protein from a protein solution, which comprises
5 immobilizing an antibody in accordance with claim 66 to a substrate or solid support, contacting said immobilized antibody with a solution containing said protein under conditions suitable for the formation of immune complexes between said antibody and said
10 protein, separating unbound protein from protein bound to said antibody, and releasing said bound protein from said antibody and recovering said protein.

133. A composition comprising viral proteins isolated from a viral lysate which has been treated to remove human HLA class I and class II antigens present in said lysate, wherein said proteins have been

5 deglycosylated and wherein said proteins comprise at
least one epitope region which does not elicit an
immune response in man when encountered through
infection environmental exposure but does elicit an
immune response in at least one non-human mammalian
10 species.

134. A composition in accordance with claim 133,
wherein said epitope region encompasses a neutralizing
or inactivating region of said viral protein.

135. A composition in accordance with claim 133,
wherein said epitope region has an amino acid sequence
which corresponds to or immunologically mimics a
portion of a human protein amino acid sequence.

136. A composition in accordance with claim 133,
wherein said proteins are coupled to a macromolecular
carrier.

137. A composition in accordance with claim 136,
wherein said carrier is a muramyl dipeptide
microparticle.

138. A composition in accordance with claim 136,
wherein said muramyl dipeptide comprises a terminal
dipeptide of L-alanine-D-isoglutamine.

139. A composition comprising a synthetic peptide
which comprises an epitope region which corresponds to
or mimics a neutralizing or inactivating region of a
viral protein, wherein said peptide does not elicit an
5 immune response in humans when encountered through
infection or environmental exposure but does elicit an
immune response in at least one non-human mammal.

140. A composition in accordance with claim 139,
wherein said epitope region has an amino acid sequence
which corresponds to or immunologically mimics a
portion of a human protein amino acid sequence.

141. A composition in accordance with claim 139, wherein said proteins are coupled to a macromolecular carrier.

142. A composition in accordance with claim 141, wherein said carrier is a muramyl dipeptide microparticle.

143. A composition in accordance with claim 141, wherein said muramyl dipeptide comprises a terminal dipeptide of L-alanine-D-isoglutamine.

144. A method for identifying a neutralizing or inactivating region of a viral protein, wherein said neutralizing or inactivating region does not elicit an immune response in man when encountered through
5 infection or environmental exposure but does elicit an immune response in a non-human animal, which comprises:
 (a) extracting viral proteins from a viral lysate;
 (b) immunizing a non-human mammal with said extract;
10 (c) obtaining antisera from said immunized mammal;
 (d) employing said antisera in a competitive immunoassay with human viral antisera to identify regions of viral proteins which are recognized by antibodies in said antisera but not recognized by
15 antibodies in said human sera; and
 (e) determining which of said regions is a neutralizing or inactivating region.

145. A method for obtaining antibodies which react with an epitope on a neutralizing or inactivating region of a protein, wherein said neutralizing or inactivating region of said protein fails to elicit an
5 immune response in man when encountered through infection or environmental exposure but does elicit an immune response in a non-human mammal which comprises:
 (a) isolating proteins from a viral lysate;

145

- 10 (b) identifying an epitope on at least one of said proteins which has an amino acid sequence which corresponds to or mimics the amino acid sequence of a neutralizing or inactivating region which fails to elicit an immune response in man but does elicit an immune response in a non-human mammal;
- 15 (c) combining said proteins with a physiologically acceptable carrier;
- (d) immunizing a non-human mammalian host with said proteins and carrier; and
- 20 (e) obtaining antibodies to said epitope from said immunized host.

146. A method in accordance with claim 145, wherein said proteins are treated to remove HLA class I and class I antigens and to remove carbohydrates prior to being combined with said physiological carrier.

147. A method in accordance with claim 146, wherein said proteins are conjugated to a macromolecular carrier comprising a muramyl dipeptide microparticle prior to being combined with said
- 5 physiological carrier.

148. A method for obtaining antibodies which react with an epitope on a neutralizing or inactivating region of a viral protein, wherein said neutralizing or inactivating region of said protein fails to elicit
- 5 an immune response in man when encountered through infection or environmental exposure but does elicit an immune response in a non-human mammal, which comprises:
- (a) synthesizing a peptide having an amino acid sequence which corresponds to or mimics an epitope
- 10 on a neutralizing or inactivating region of a viral protein, wherein said region fails to elicit an immune response in man but does elicit an immune response in a non-human mammal;

- 15 (b) combining said peptide with a physiologically acceptable carrier;
(c) immunizing a non-human mammalian host with said peptide and carrier; and
(d) obtaining antibodies to said epitope from said immunized host.

149. A method in accordance with claim 148, wherein said proteins are treated to remove HLA class I and class I antigens and to remove carbohydrates prior to being combined with said physiological carrier.

150. A method in accordance with claim 149, wherein said proteins are conjugated to a macromolecular carrier comprising a muramyl dipeptide microparticle prior to being combined with said
5 physiological carrier.

151. An antibody which recognizes and reacts with an epitope which corresponds to or mimics an epitope on a neutralizing or inactivating region of a viral protein, wherein said neutralizing or inactivating
5 region of said protein fails to elicit an immune response in man when encountered through infection or the environmental exposure.

152. A combination of at least two antibodies, each of which recognizes and reacts with an epitope which corresponds to or mimics an epitope on a neutralizing or inactivating region of a viral protein,
5 wherein said neutralizing or inactivating region of said protein fails to elicit an immune response in man when encountered through infection or environmental exposure.

153. A method of inhibiting a viral infection in a human infected with the virus which comprises administering to said patient a therapeutically effective amount of a composition comprising one or
5 more antibodies each of which recognizes and reacts

with an epitope which corresponds to or mimics an epitope on a neutralizing or inactivating region of a protein of the virus, wherein said neutralizing or inactivating region of said protein fails to elicit an immune response in man when encountered through infection or environmental exposure.

154. A method in accordance with claim 153, wherein said antibodies are conjugated to muramyl dipeptide microparticles.

155. A method for preventing a viral infection in a patient who has been exposed to the virus which comprises administering to said patient a therapeutically effective amount of a composition comprising one or more antibodies each of which recognizes and reacts with an epitope which corresponds to or mimics an epitope on a neutralizing or inactivating region of an HIV protein, wherein said neutralizing or inactivating region of said protein fails to elicit an immune response in man when encountered through infection or environmental exposure.

156. A method for detecting the presence of a virus in a biological fluid sample from an individual who may have been infected with the virus which comprises employing an antibody of claim 150 in an antibody-antigen assay in which said antibody is combined with a sample of body fluid from said individual under conditions conducive to antibody-antigen complex formation and determining whether said antibody binds to an antigen of the virus.

157. A method for detecting the presence of a virus in an individual who may have been infected with the virus which comprises employing an antibody of claim 151 in an enzyme immunoassay, wherein said antibody is conjugated to an enzyme and contacted with

a sample of body fluid from said individual under conditions conducive to antibody-antigen complex formation and determining whether said antibody binds to an antigen of the virus.

158. A method for purifying protein containing at least one epitope which corresponds to or mimics an epitope of a neutralizing or inactivating region of a viral protein from a protein solution, which comprises
5 immobilizing an antibody in accordance with claim 150 to a substrate or solid support, contacting said immobilized antibody with a solution containing said protein under conditions suitable for the formation of immune complexes between said antibody and said
10 protein, separating unbound protein from protein bound to said antibody, and releasing said bound protein from said antibody and recovering said protein.